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ABSTRACT 
The effects of microfluidization and homogenization on the structure of liposomal 
aggregates from whey buttermilk and commercial buttermilk  
Tracey Mai T. Nguyen 
Milk derived ingredients from the production of cheese and butter can be used as 
vehicles for nutrients. Buttermilk is a nutritious product of milk that comes from the 
churning of cream into butter.  One of the advantages of buttermilk is that it is enriched in 
milk fat globule components, such as phospholipids and forms emulsions with fat when 
treated with high shear. The objective of this work was to explore the effects of shear on 
regular buttermilk and whey buttermilk in terms of liposomal aggregate size and 
chemical composition. The effects of microfluidization at 2000 psi and homogenization 
at 2000 psi/500 psi on the particle size distribution of liposomal aggregates between 
whey buttermilk (WBM) at pH 4.6 and 6.8 and commercial sweet buttermilk (SBM) at 
pH 4.60 were compared with whey protein isolate (WPI) at pH 4.6. At pH 6.80, WPI and 
SBM are too soluble in water to measure particle size but WBM is not as soluble. From 
this investigation, the mean particle diameter of the SBM aggregates at pH 4.6 decreased 
after the first pass through the microfluidizer and the same is true, after homogenization. 
SBM aggregates at pH 4.6 had a significantly larger mean particle diameter before 
treatments in both shear processes compared to WPI at pH 4.6 and WBM at pH 4.6 and 
WBM at pH 6.8 (p < 0.0001). WPI at pH 4.6 and WBM at both pH showed no significant 
differences in their mean particle size in both homogenized and microfluidized 
treatments. WPI and SBM samples resulted in significant particle diameter differences 
from before to after homogenizing at pH 4.6. SBM at pH 4.6 had significantly larger 
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average particle diameter than WBM at pH 4.6 (p < 0.0002), WPI at pH 4.6 (p < 0.0002) 
and WBM at pH 6.8 (p < 0.0045) before microfluidization at pass 0.  
WBM and WPI across all treatments showed very similar tendencies in small 
particle size attributes and some similarities in protein composition. In addition, the small 
aggregate size of WBM is suggested to be influenced by the presence of phospholipids 
and thus, creating significantly smaller mean particles compared to SBM even before 
inducing high shear. In contrast, treated and untreated SBM differed from WBM in 
phospholipid composition in both homogenization and microfluidization techniques. 
WBM samples contained more phospholipids than SBM, whereas WPI samples 
contained very low concentrations of phospholipids. Through HPLC analysis, WPI, 
SBM, and WBM showed different profiling of the phospholipid classes. These 
differences may be due structural changes of the aggregates from shearing, initial thermal 
treatments or hydrophobic and/or protein-phospholipid interactions between the 
aggregates. SBM samples also exhibited different protein profiling than WBM and WPI 
samples. This study suggests that high shear and presence of phospholipids impact the 
size distribution of liposomal aggregates through structural alterations. The aggregates 
can be utilized as a novel ingredient and in the processing of dairy foods to deliver 
nutrition. 
Keywords: milk fat globule membrane (MFGM), phospholipids, microfluidization, 
homogenization, delivery system.  
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1.0 Introduction 
Milk is defined as a fluid secreted by all female mammalian species to supply 
nutrients and provide immunological and anti-bacterial protection to the neonate (Fox & 
McSweeney, 1998). Milk is widely known as a nutritious and beneficial beverage with an 
excellent source of protein, calcium, vitamins, and minerals. Despite the nutritious 
benefits of milk, the per capita consumption of fluid milk in the United States has 
declined since 1970 from 0.96 cup-equivalents to 0.61 cup-equivalents per day (Stewart, 
Dong, & Carlson, 2013). According to the USDA, about 20,834 million pounds of 
conventional fluid milk products were sold in May of 2013 in the United States, year to 
date. Compared to last year, these numbers represent a 1.6% decrease in fluid milk sales 
(USDA, 2013).  
Despite the fall in fluid milk consumption, the overall dairy consumption per 
capita still remains steady at 1.5 cup-equivalents per day, with a rising consumption of 
cheese (Stewart, Dong, & Carlson, 2013). Additionally, the production and consumption 
of dry buttermilk has been increasing every year since 2009 (Figure 1.1) (USDA, 2013). 
Buttermilk is traditionally made from the churning of sweet cream into butter. This 
process releases a liquid co-product known as buttermilk. There are many other sources 
buttermilk that exists such as cultured buttermilk and whey buttermilk (Sodini, Morin, 
Olabi, & Jimenez-Flores, 2006). Buttermilk is also considered a nutritious dairy 
ingredient that is saturated in milk fat globule membrane (MFGM) components. These 
components consist of phospholipids and proteins that have been attributed to be 
advantageous and beneficial. The MFGM constituents, especially phospholipids, have 
been shown to possess abilities that prevents colon cancer, suppress H. pylori infections, 
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and inhibits intestinal absorption of cholesterol (Spitsberg, 2005) (Parodi, 1997) 
(McDaniel, Maier, & Einstein, 2002) (Sprong, Hulstein, & Van Der Meer, 2002).     
 
 
Figure 1.1. Production trends of dry buttermilk from 2009 to 2013 in the United States 
adapted from the USDA (2013). 
Over the last several decades, chronic ailments and diseases have been increasing 
worldwide. There is a great need for cures and preventative measures for diseases like 
hypercholesterolemia, diabetes, and cancer. Further research is needed to study how 
nature’s most nutritious beverage can help prevent and cure diseases. Research on the 
development of novel ingredients and innovative techniques can also help put nutrition 
and beneficial elements back into our bodies. Phospholipids from the MFGM can be 
utilized as a delivery system for bioactive components such as active drugs, flavor 
compounds, and vitamins, for functional use in the nutraceutical, pharmaceutical, and 
food industries. 
This thesis focuses on structural and compositional comparisons of liposomal 
aggregates from commercial sweet buttermilk and whey buttermilk prepared by 
microfluidization and homogenization. The induction of high shear structurally effects 
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the formation of liposomes. By utilizing two shearing types, a comparison can be made 
on which mechanisms will produce smaller liposomes for more functional and practical 
applications in food products. The investigation of aggregate size is important not only in 
functionality, but also texturally. This research takes a look at liposomal aggregates from 
sweet buttermilk and whey buttermilk at the physicochemical level to assess its size 
distribution, phospholipid profiling, and protein composition. Ideas from this 
investigation contributes to current knowledge and research of utilizing liposomes as 
vehicles for delivering nutrients.    
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2.0 Literature Review 
2.1 Origin and Function of MFGM 
Bovine milk contains 3-5% fat that is dispersed in the form of small droplets. 
Roughly 97-98% of the total lipids in milk are composed of triacylglycerols (TAG) and 
less than 1% represents phospholipids. The fat droplets range in diameter from 0.1 µm to 
20 µm and average 3.5 µm (Fox & McSweeney, 1998). Many factors influence the fat 
globule size distribution and composition including cow breed, stage of lactation, diet, 
and seasons. Lipids are insoluble in water and great tension to exist between the 
dispersed lipids and water causing coalescence, or fusion of lipids, to occur. Emulsifiers 
are surface active agents used to prevent coalescence by forming a film around the fat 
globules, which reduces the surface tension and protects the lipids from enzymatic 
reactions. In unprocessed milk, the milk fat globule membrane (MFGM) exists as a 
natural emulsifier and provides a protective layer around the fat globules (Singh, 2006).   
 
Figure 2.1. A representation of the milk fat globule membrane adapted from Lopez et al., 
(2010) 
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The MFGM is a tri-layer membrane originating from the rough endoplasmic 
reticulum (rER) and the apical membrane of epithelial secretory cell of the mammary 
gland (Figure 2.1) (Fox & McSweeney, 1998). Milk fat globules are synthesized in the 
rER in the form of small droplets and fuse together to give rise to larger droplets (Singh, 
2006). The droplets are primarily made of TAGs and are protected by a surface coat 
derived from the rER. This surface coat is comprised of cholesterol and major 
phospholipids including phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
sphingomyelin (SM), phosphatidylinositol (PI), and phosphatidylserine (PS) (Fox & 
McSweeney, 1998).  It provides stability to the fat globule and is the most inner layer of 
the MFGM. Once the fat globules are secreted from the rER, it travels through the 
cytoplasm towards the apical membrane. During secretion, the outer apical lipid bilayer 
surrounds the fat globules and is released from the cell (Singh, 2006). 
 
Figure 2.2. A diagram of the synthesis and secretion of milk constituents from apical 
membrane of the epithelial cell of a mammary gland adapted from Keenan et al., (1988). 
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There are three mechanisms in which the secretory vesicles containing fats, 
proteins and other milk constituents interact with the apical plasma membrane. According 
to Dylewski and Keenan (1983), the secretory vesicles form a chain of fused vesicles to 
release contents outside of the cell. Alternatively, individual vesicles may incorporate its 
membrane with the apical membrane in order to discharge its contents by exocytosis. 
Frank et al. (1976) and Dylewski & Keenan (1983) described the third and most accepted 
mechanism as a direct envelopment or “budding” of the fat globule. As the globule 
journeys to the apical pole it is engulfed by the plasma membrane and buds from the cell. 
Figure 2.2 shown above illustrates these mechanisms.     
2.2 Composition of MFGM 
2.2.1 Proteins 
Bovine milk contains approximately 2.0-3.5% protein (Fox, 2003) (Fox & 
McSweeney, 1998). Milk proteins are synthesized in the ER, transported to the Golgi 
Apparatus (GA), and integrated in the secretory vesicle along with lactose and other milk 
components (Keenan, Mather, & Dylewski, 1988). Protein accounts for 25-60% of the 
total dry weight of the MFGM (Keenan & Dylewski, 1995). The MFGM is comprised of 
over 40 proteins and some principle proteins are xanthine oxidase (XO), butyrophilin 
(BTN), and periodic acid/Shiff 6 and 7 (PAS 6 and 7) (Singh & Ye, 2010). A summation 
of the major and minor MFGM proteins is listed along with their molecular weights in 
Table 2.1.  
Xanthine oxidase has a molecular weight of 150 kDa and accounts for 10- 20% of 
the total MFGM protein (Singh, 2006). Its complex is part of the iron-sulfur-molybdenum 
flavin hydroxylase family, which converts xanthine to uric acid (Singh, 2006) (Keenan, 
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Mather, & Dylewski, 1988). At least 60% of XO is associated with the MFGM derived 
from the apical membrane as it is removed from washing with non-ionic detergents or 
high salt concentrations (Keenan, Mather, & Dylewski, 1988). XO can act as an 
antimicrobial agent by producing free radicals and hydrogen peroxide in vivo (Keenan, 
Mather, & Dylewski, 1988).  
Table 2.1. Protein composition of bovine milk fat globule membrane modified from 
Singh (2006) and Keenan and Dylewski (1995). 
Protein Molecular Weight (kDa) 
Mucin I (MUC I) 160-200 
Xanthine Oxidase (XO) 150 
PAS III 95-100 
CD36 or PAS IV 76-78 
Butyrophilin (BTN) 67 
Adipophilin (ADPH) 52 
PAS 6/7 48-54 
Fatty acid binding protein (PABP) 13 
BRCA1 210 
 
Butyrophilin has a molecular weight of 67 kDa and is described as an insoluble, 
hydrophobic glycoprotein that has a high affinity for binding with lipids (Keenan, 
Mather, & Dylewski, 1988). It is mainly found on the apical surface of the MFGM and 
plays a key role on the enclosure and stability of the fat globules during secretion 
(Keenan, Mather, & Dylewski, 1988). BTN is highly associated with the MFGM and has 
strong interactions with other proteins, making it difficult to purify by salts and active 
detergents (Keenan & Dylewski, 1995). Thus, sodium dodecyl-sulfate polyacrylamide 
(SDS-PAGE) gels are used to successfully separate and elute this protein from the 
membrane. 
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PAS 6 and PAS 7 are two types of glycoproteins with molecular weights ranging 
from 48-54 kDa (Singh, 2006). The amino acid sequences of these proteins are the same; 
however, they differ in the glycosylation with carbohydrates (Hvarregaard, Anderson, 
Berglund, Rassmussen, & Petersen, 1996). Their exact structure and function is not yet 
known but can be easily visualized in SDS-PAGE gels with periodic acid/Schiff’s reagent 
or by staining with Coomassie Blue. 
Milk contains two major heterogeneous proteins – caseins and whey proteins – 
which interact with the surface of the MFGM. Milk also contains blood serum albumin 
(BSA), immunoglobulins, lactotransferrin, and enzymes (i.e. lipases), but these 
components are not investigated in this research. The biological function of casein is to 
provide calcium from mother to neonate. Caseins are structurally complex and consist of 
several components including α-, β-, γ-, and κ-casein. Together, these components 
represent the entire composition of the protein. Caseins associate with the MFGM by 
disulphide bonding between the κ-casein and MFGM proteins or by sulphydryl-
disulphide (SH-SS) interchanges with the MFGM proteins (Singh & Ye, 2010). They 
mainly exist in the form of spherical micelles, which range from 50-500 nm in diameter 
(Fox & McSweeney, 1998). Cheese is manufactured by precipitating caseins from milk 
by acidification or rennet (enzyme) coagulation. Caseins coagulate at the isoelectric point 
of 4.6 at 20 °C (Fox, 2003). At these conditions, caseins readily form large aggregates 
and precipitate from solution.   
 Whey (serum) proteins represent about 20% of the total proteins in bovine milk 
(Fox, 2003). Whey proteins are described as the globular proteins, which are roughly 3.6 
nm in diameter, that remain in the milk serum after the precipitation of caseins at pH 4.6 
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at 20 ºC (Fox & McSweeney, 1998)(Whitney, 1988). Like caseins, whey proteins contain 
several components: β-lactoglobulin (β-Lg) and α-lactalbumin (α-La). β-Lg has a 
molecular weight of 18 kDa and represents approximately 50% of whey proteins in the 
milk of bovine, sheep, and goat (Fox, 2003). However, it is not present in human, mouse 
or guinea pig milk. β-Lg is also complex in structure and contains an abundant amount of 
sulfur amino acids, cysteine, and two intramolecular disulfide bonds (Fox, 2003). These 
bonds play a role in the association of whey proteins with the MFGM. The disulfide 
bonds can participate in SH-SS interchanges when denatured with heat, which will be 
discussed later in Section 2.5.3. Lastly, α-La accounts for about 20% of whey protein and 
is the principle protein in human, mouse, and guinea pig milk (Fox & McSweeney, 
1998). It is a less complex globular protein that has a molecular weight of about 14 kDa 
(Fox, 2003). It is rich in some amino acids, including tryptophan and methionine, and 
contains four intramolecular disulfide bonds (Fox & McSweeney, 1998). Bovine α-La is 
synthesized in the mammary gland and is a component of lactose synthetase, which plays 
an important role in the production of lactose (Fox, 2003) (Whitney, 1988).  
2.2.2 Lipids 
Lipids account for approximately 2-6% of the total weight of the milk fat globule 
and is reported to contain 0.5-1.1 mg of lipid/ mg of protein (Singh, 2006) (Keenan, 
Mather, & Dylewski, 1988). The MFGM is comprised of neutral lipids (triglycerides, 
diglycerides, sterols, and free fatty acids) and polar phospholipids that surround the fat 
globule for stability and prevent enzymatic degradation by lipases (Rombaut & 
Dewettinck, 2006). Triglycerides make up the majority of the milk fat globule core and 
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part of the membrane, while diglycerides, sterols, and free fatty acids make up less than 
10% of the MFGM (Table 2.2).     
Table 2.2. Lipid composition of bovine milk fat globule membrane adapted and modified 
from Singh (2006) and Keenan and Dylewski (1995). 
Constituent Class % of total lipids 
Triglycerides 62 
Diglycerides 9 
Sterols 0.2-2.0 
Free fatty acids 0.6-6.0 
Phospholipids 26-31  
Sphingomyelin 22 
Phosphatidylcholine  36 
Phosphatidylethanolamine 27 
Phosphatidylinositol 11 
Phosphatidylserine 4 
Lysophosphatidylcholine  2 
 
Phospholipids are amphiphilic molecules with a hydrophilic head and a 
hydrophobic tail. The major classes of phospholipids in order of abundance are PC, PE, 
SM, PI, and PS (Table 2.2). Specifically, the MFGM is rich in PC, PE, and SM in a 2:2:1 
ratio (Fox & McSweeney, 1998). PC, PE, PI, and PS are all part of the 
glycerophospholipid family consisting of a glycerol backbone with two fatty acids 
esterified on the sn-1 and sn-2 positions and a phosphate residue with different organic 
groups on the sn-3 position (Figure 2.3) (Fox, 2003) (Rombaut & Dewettinck, 2006). In 
contrast, SM is part of the sphingolipid family consisting of ceramide, which contains a 
long-chain sphingosine backbone attached to phosphocholine (Dewettinck, et al., 2008). 
SM and PC are largely situated outside of the membrane while PE, PS, and PI are 
generally concentrated on the inner surface (Rombaut & Dewettinck, 2006). These polar 
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phospholipids contain phosphorous, which acts as an emulsifier that keeps the globule in 
suspension due to its positive and negative charge (Fox & McSweeney, 1998).  
 
Figure 2.3. Chemical structures of polar phospholipids of the MFGM (Contarini & 
Povolo, 2013) 
The MFGM contains an essential number of phospholipids that can provide health 
benefits. Some studies claim that PC and PS are “brain-specific” nutrients and aide in 
enhancing memory performance in older adults with Alzheimer’s disease and recollection 
of words, while others show inconclusive results (McDaniel, Maier, & Einstein, 2002). 
SM, for example, is known for its contribution to a number of health advantages and has 
been greatly studied. In a study by Noh and Koo (2004), milk SM was found to be 
effective in inhibiting the intestinal absorption of cholesterol and other lipids in adult 
male rats. They suggest that the inhibitory effects are associated with the saturation of 
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longer chain fatty acid groups of SM derived from milk, which cause the rate of luminal 
lipolysis, micelle solubility, and transfer of lipids to the enterocyte to decrease (Noh & 
Koo, 2004). SM also exerts anti-carcinogenic activity by inhibiting cell growth, induction 
of differentiation, and apoptosis (Parodi, 1997). Mice with multiple intestinal neoplasia 
(Min) were fed SM and showed a reduced numbers of colon tumors and aberrant crypt 
foci (Parodi, 1997). Animal and in vitro studies have also shown that bovine fat and 
shingolipids enhance resistance to certain types of food-borne gastrointestinal pathogens 
(Sprong, Hulstein, & Van Der Meer, 2002).  
2.3 Sources of MFGM 
Cream, whole milk, and buttermilk are excellent sources of MFGM constituents 
and can be extracted using several methods of isolation (Singh, 2006) (Fox & 
McSweeney, 1998). Buttermilk is considered the most important source of MFGM 
material because it is enriched in essential phospholipids and proteins (Jimenez-Flores & 
Brisson, 2008). Buttermilk is the liquid by-product of churning cream into butter (Figure 
2.4). Butter churning involves a phase inversion from oil-in-water emulsion of cream or 
whole milk to a water-in-oil emulsion (Fox & McSweeney, 1998). This is achieved by 
mechanical agitation to disrupt the MFGM and expose globular fats, followed by 
kneading or working to release fat liquids and subsequently form clumps of fat known as 
butter (Fox & McSweeney, 1998). The fat liquid is referred to as sweet buttermilk or 
cultured (sour) buttermilk if inoculated with lactic acid bacteria. The MFGM material is 
largely lost in the buttermilk, thus making it a great source of phospholipid.  
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Figure 2.4. Butter manufacturing flow diagram adapted and modified from O’Mahony 
(1988). 
In this research, sweet buttermilk and whey buttermilk powder was used to 
compare liposomal aggregates. The compositions of the ingredients used in this project 
are shown in Table 2.3. Sweet buttermilk powder (SBM) is commercially produced, rich 
in phospholipids, and contains caseins and whey proteins. It is used in various food 
products, such as baked goods, for flavor and in salad dressings for its emulsification 
properties (Morin, Pouliot, & Jimenez-Flores, 2005). Whey buttermilk powder (WBM) is 
a novel dairy ingredient that is free of non-polar lipids and made from whey cream and 
treated with supercritical fluid extraction. The production of whey buttermilk powder is 
described in Section 3.1. In a study by Elias-Argote (2011), whey buttermilk was shown 
to be even more enriched with phospholipids and contain more proteins than sweet 
buttermilk (Table 2.4). Lastly, whey protein isolate (WPI) was used as the control in this 
research to compare the effects of phospholipids on aggregation. 
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Table 2.3. Composition of dairy powders.  
Product 
% Dry Matter 
Protein Fat Lactose Ash 
Whey Protein Isolate 
(WPI) 
93.00 0.50 1.50 2.50 
Sweet Buttermilk Powder 
(SBM) 
32.46 9.17 ND 7.36 
Whey Buttermilk Powder 
(WBM) 
72.10 ± 5.10* 20.3 ± 0.80* 4.8 ± 1.40* 2.7 ± 0.20* 
* Percent standard deviation; ND = Not Determined. 
Table 2.4. Phospholipid and protein composition in various dairy products adapted from 
Elias-Argote (2011). 
 
Product 
Phospholipids (g/100g) Protein % 
Wet basis Dry basis Wet basis Dry basis 
Raw milk 0.035 0.280 3.30 - 
Skim milk 0.020 0.280 3.41 7.55 
Cream 0.190 0.400 3.16 - 
Isolated MFGM 0.650 6.500 1.80 60.00 
Butter 0.190 0.230 0.85 - 
Sweet Buttermilk 0.160 2.030 3.31 32.95 
Butterserum 1.250 11.50 - - 
Fresh acid sour buttermilk 0.310 1.860 3.31 - 
Acid buttermilk whey 0.100 1.840 0.99 84.70 
WBP* - 14.81 - 47.39 
SPE-WBP*
 
- 60.59 - 72.69 
Cheddar cheese 0.150 0.250 - 24.89 
Cheddar cheese whey 0.020 0.260 3.49 35.20 
*Abbreviations: WBP= whey buttermilk powder; SPE= solid phase extraction. 
 
2.4 Health Benefits and Food Applications of MFGM 
Over the last two decades, researchers have accumulated a great deal of 
knowledge on the health benefits of bovine MFGM components. The MFGM contains an 
abundant number of proteins and phospholipids, which can be beneficial and functional 
in food and nutraceutical applications (Morin, Pouliot, & Jimenez-Flores, 2005). 
Membrane proteins are one contributor to functional and beneficial health including anti-
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cancer effects. Studies have shown that the fatty acid binding protein (FABP), isolated 
from bovine MFGM, inhibits several in vivo breast cancer cell line growth (Spitsberg, 
2005). Additionally, BRCA1 protein, an onco-suppressor, was found to be present in both 
bovine and human MFGM (Spitsberg, 2005). In a study by Wang et al. (2001), 
glycoproteins from bovine MFGM demonstrated inhibition of Helicobacter pylori 
infection of the gut mucosa in a mouse model. The glycoproteins used in Wang’s 
experiments were extracted from bovine buttermilk, administered orally to mice with the 
H. pylori infection, and resulted in healing of the infection in the gastric mucosa. Another 
glycoprotein, BTN, was found to regulate T-cell response to the myelin oligodendrocyte 
glycoprotein (MOG) in mice models with inflammatory demyelinating disease of the 
brain, which correlates to human multiple sclerosis (Spitsberg, 2005).       
The MFGM is enriched in phospholipids which also exert some anti-carcinogenic 
effects. As discussed previously, SM was shown to suppress and reduce colon cancer 
cells in mice, and SM derivatives were shown to induce apoptosis in adenocarcinoma 
human cell line (Parodi, 1997) (Spitsberg, 2005). Furthermore, SM was demonstrated to 
be an effective intestinal inhibitor of absorbing cholesterol in rats (Noh & Koo, 2004). 
Phospholipids also contribute to growth and development, cellular transport and 
absorption, and central nervous system myelination (McDaniel, Maier, & Einstein, 2002) 
(Spitsberg, 2005).  
Membrane components of the milk fat globule MFGM material extracted from 
buttermilk or cream are considered an efficient emulsifying agent. Phospholipids in 
MFGM play an important role in stabilizing fat globules in oil-in-water emulsions and 
protecting the core from enzyme degradation (Singh, 2006). Phospholipids can be 
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incorporated in food systems as emulsifying agents since its natural function is to 
maintain the structure of the globules and keep them in suspension. These unique 
attributes of phospholipids have led to extensive research in developing technologies for 
isolating MFGM material for novel functional foods and nutraceutical applications.  
Phospholipids derived from MFGM can be utilized as a delivery system in the 
food, pharmaceutical, and cosmetic industries (Thompson, Mozafari, & Singh, 2007). 
Delivery systems, in the form of liposomes, are commonly used to encapsulate agents 
such as active drugs, flavor compounds, vitamins, and enzymes (Nongonierma, Abrlova, 
Fenelson, & Kilcawley, 2009). Liposomes are defined as spherical vesicles, or structures, 
consisting of a single or multiple phospholipid bilayers surrounding an aqueous core 
(Figure 2.5) (Thompson & Singh, 2006). There have been many studies carried out on 
the encapsulation of active ingredients using liposomes as a mode of transport. 
Nongonierma et al. (2009) evaluated food grade liposomes to encapsulate 
commercialized enzyme extract that decrease bitterness in protein hydrolysates and 
cheese. Thompson and Singh (2006) (2007) looked at various techniques of preparing 
liposomes via microfluidization, and Benjamin et al. (2012) investigated liposomes as 
carriers for volatile organic compounds such as flavors. Bezelgues et al. (2008) 
demonstrated a two-fold incorporation of α-tocopherol, a form of Vitamin E, and 
lycopene in mixed micelles using MFGM material. Together, these studies confirmed 
functional and beneficial use of liposomes derived from bovine MFGM as vehicles for 
nutrient transport.   
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Figure 2.5. Typical structure of a liposomal vesicle adapted from McClements (2005). 
Not only do MFGM proteins and phospholipids contribute health attributes and 
functional properties in food systems, but they also influence texture.  The MFGM can be 
considered as a stabilizer or surfactant because it contains phospholipids to enhance the 
stability of an emulsion (McClements, 2005). Stabilizers are added to foods to reduce the 
rate of creaming, increase viscosity of a continuous phase, and modify texture by 
thickening or gelling. MFGM constituents can be incorporated into foods like baked 
goods, chocolate, spreads, and beverages for stabilization. To better understand texture, 
we must study how liposomal particles behave on a molecular level. Hydrophobic 
interactions are said to be the main driving force of liposome formation, which causes the 
liposomes to reduce unfavorable contact between the hydrophobic tails of phospholipids 
and water (McClements, 2005). Additionally, proteins also interact with each other and 
the MFGM via disulfide bonding and hydrophobic interactions, which causes unique 
texture attributes such as foaming (Bouaouina, Desrumaux, Loisel, & Legrand, 2006).  
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2.5 Physiochemical Effects of Processing on Phospholipids and MFGM 
2.5.1 Homogenization 
High pressure, two-stage valve homogenizers are generally used to manufacture 
fluid milk and milk products because of its ability to effectively minimize droplet size 
(Fox & McSweeney, 1998)(McClements, 2005). In industry, milk is homogenized in two 
stages by forcing liquid milk through a small orifice. In the first stage the milk is forced 
at a high pressure, usually 2000 psi, at 40ºC (Figure 2.6). During this stage, the average 
diameter of the fat globules have significantly decreased through actions of high shear, 
collision, and distention, which results in high viscosity due to the small fat globules 
clumping together (Fox & McSweeney, 1998). In the second stage, the homogenization 
pressure is lowered to about 500 psi to reduce viscosity by dispersing the fat clumps 
(McClements, 2005).  
 
Figure 2.6. Homogenizer mechanism diagram adapted from Spence et al. (2010). 
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Homogenization techniques can be utilized to generate liposomes and aggregates 
for use in various applications. Upon homogenization, fat globules are disrupted which 
result in globule size reduction and an increase in their specific surface area (Zamora, 
Ferragut, Guamis, & Trujillo, 2012). Milk processing triggers physicochemical 
interactions between MFGM constituents and whey proteins and caseins (Zamora, 
Ferragut, Guamis, & Trujillo, 2012). Figure 2.7 illustrates this phenomenon of non-
native MFGM protein adsorption. Ye et al. (2008) investigated changes in the surface 
proteins of fat globules during homogenization with heat treatments and found that the 
amount of native MFGM proteins was not changed during homogenization. Many studies 
have suggested that caseins and whey proteins do not alter the conformation of MFGM 
proteins but rather are adsorbed onto the surface of the MFGM (Ye, Anema, & Singh, 
2008) (Zamora, Ferragut, Guamis, & Trujillo, 2012) (Bouaouina, Desrumaux, Loisel, & 
Legrand, 2006) (Lee & Sherbon, 2002).  
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Figure 2.7. A representation of the MFGM in homogenized milk (Fox & McSweeney, 
1998).  
2.5.2 Microfluidization 
Microfluidization is another type of homogenizer and is a technique that can 
rapidly create high volumes of emulsions with very small globule sizes (McClements, 
2005) (Thompson & Singh, 2006). A microfluidizer consists of a fluid inlet, an air motor 
pumping at high pressure, and an interaction chamber where two channels of fluid flow at 
high velocity and collide with each other (Figure 2.8) (McClements, 2005). When the 
fluids from the two channels collide, it generates intense, disruptive forces that result in 
very small emulsion droplets. Like homogenization, this technique triggers 
physicochemical interactions between MFGM components and whey proteins and 
caseins and has been utilized to prepare liposomes and aggregates for functional 
applications in different industries. This technique is also suitable for use in the food 
industry because it does not require the use of detergents or solvents (Thompson & 
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Singh, 2006). As mentioned previously, Nongonierma et al. (2009) evaluated liposome 
encapsulation of commercial enzymes using microfluidization, which resulted in high 
encapsulation capacity of the enzymes. Thompson and Singh (2006) (2007) also 
investigated liposomal preparation using a microfluidizer at various pressures and 
number of passes.  
 
Figure 2.8. Microfluidizer mechanism diagram modified from Spence et al., (2010). 
2.5.3 Temperature and pH 
Temperature and pH play principle roles in the physical and chemical changes of 
lipids and proteins and are inversely related to each other. The pH of milk at 25 ºC is 
usually 6.5-6.7 and its pH is heavily influenced by temperature than pH (Fox & 
McSweeney, 1998). With higher thermal treatments, the pH of milk will decrease due to 
lactose degradation to organic acids (Fox & McSweeney, 1998). Lipids do not have 
significant changes in pH because they are least effected by heat. When milk is heated to 
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approximately 70 ºC, a group of immunoglobulins called cryoglobulins, which are 
responsible for the aggregation and creaming of fat globules, are irreversibly denatured 
and prevent creaming from occurring (Fox & McSweeney, 1998). Foaming may also 
occur with heat treatment and agitation due to changes in the MFGM (Fox & 
McSweeney, 1998).   
In whey proteins, temperatures above 70 ºC cause denaturation by exposing and 
activating free SH group in cysteine residues (Fox & McSweeney, 1998).This causes the 
release of hydrogen sulfide (H2S), which is responsible for the undesirable cooked flavor 
in milk, and disulfide interchanges with β-Lg and  α-La at the pH of milk, eventually 
resulting in aggregation and attachment on the fat globules (Fox & McSweeney, 1998) 
(Dalgleish, Senaratne, & Francois, 1997) (De Wit, 2009). However, at acidic conditions 
the free SH groups are considered to be inactive (Dissanayake, Ramchandran, Piyadasa, 
& Vasiljevic, 2013). Hydrogen bonding has been suggested to be responsible for 
increasing the thermal stability of proteins at low pH (Dissanayake, Ramchandran, 
Piyadasa, & Vasiljevic, 2013). Caseins, on the other hand, are thermally stable. However, 
a component of casein, κ-caseins, form aggregates with denatured β-Lg via disulfide 
interchanges and hydrophobic interactions when heated at 85 ºC-90 ºC at pH 6.8 (Brown, 
1988).  
2.6 Techniques of Analysis 
2.6.1 Particle Size Distribution 
Particle size characterization is important in food products because it has a strong 
impact on food stability, viscosity, optical properties, and sensory attributes 
(McClements, 2005). Many industries employ particle size characterization to maintain 
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quality of products and to gain a better understanding of ingredients and processes 
(Malvern, 2012). The particle concentration is usually reported as volume percent 
(Volume %) or number percent (Number %), and the actual size of the particles are 
reported as mid-point particle radius or mid-point particle diameter (McClements, 2007). 
In this research, the particle size distribution is presented in Number % by mid-point 
particle diameter (μm).  
A variety of analytical instruments are commercially available for use in industry 
to characterize particles, such as laser diffraction, dynamic light scattering, automated 
imaging, electophoretic light scattering, and electrical pulse counting (McClements, 
2007) (Malvern, 2012). A laser diffraction particle size analyzer from Beckman Coulter 
was used in this thesis to determine the particle diameters of each sample. This 
instrument uses a laser beam to scatter light through a dilute medium to determine the 
particle size distribution. This distribution is based on the intensity of the scattered light 
and the angle at which the light is scattered (McClements, 2007). The Beckman Coulter 
LS 230 Fluid Module particle size analyzer comes with software that contains a 
mathematical model called the “Mie Theory” that can calculate the scattering pattern of a 
dispersed particulate sample from characteristics of the particulates (McClements, 
2005)(McClements, 2007).  
2.6.2 Phospholipid Analysis  
The Mojonnier Method is principally utilized in the dairy industry to measure fat 
content in milk. This method is the standard AOAC method (989.05) that uses a mixture 
of ethyl ether and petroleum ether to extract fat from both the liquid and solid samples 
into the organic layer without needing to remove moisture (Min & Boff, 2003). 
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Following extraction, the defatted solids are dried and expressed as percent fat by weight. 
This method has some limitations due to the use of ammonium hydroxide, ethers, and 
heat which can lead to oxidization and hydrolysis of phospholipids (Van der Meeren & 
Vanderdeelen, 2000)(Rombaut & Dewettinck, 2006). Cold-extraction procedures using 
chloroform and methanol, such as the Folch, Lees and Stanley method (1956), are more 
advantageous because it does not require heat and harsh chemicals that would affect the 
nature of the phospholipids (Rombaut & Dewettinck, 2006). However, the cold-
extraction technique is very time consuming and non-lipid contaminants can be co-
extracted and lead to erroneous results (Rombaut & Dewettinck, 2006). The Folch 
method is best utilized in small sample quantities as it requires the heavy use of toxic 
reagents. The Mojonnier method is best used when the lipid contents are much higher.   
 Prior to polar phospholipid analysis, a concentration and separation step is often 
carried out using solid phase extraction (SPE) to remove any contaminants, such as non-
polar lipids. Since phospholipids are present in milk at very low concentrations, this extra 
step is necessary for the fractionation of polar lipids to improve the separation of polar 
lipids on thin layer chromatography (TLC) or high pressure liquid chromatography 
(HPLC) (Bitman, Wood, Mehta, Hamosh, & Hamosh, 1984). The Bitman et al. (1984) 
method of separation was used in this thesis to separate and concentrate polar 
phospholipids for HPLC analysis. SPE was performed on Mojonnier fat extracted 
samples using small pre-packed, disposable silica cartridges. These cartridges contained 
silica particles that offered strong polar selectivity to phospholipids and could withstand 
the elution of non-polar impurities using hexane and diethyl ether.  
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Phospholipids can be separated and analyzed using a variety of techniques, 
including TLC and HPLC. In the past, TLC was commonly used to separate the 
phospholipid classes because it was simple, inexpensive, and resulted in good separation 
of lipids (Van der Meeren & Vanderdeelen, 2000). However, the quantification of 
phospholipids became a major problem because it required modern and expensive 
computer-controlled scanners. As an alternative, HPLC has become the method of choice 
to accurately separate and quantify phospholipids in dairy because the technique is highly 
flexible and easier to automate (Van der Meeren & Vanderdeelen, 2000).  
A wide variety of detectors can be used for HPLC analysis, including evaporative 
light-scattering (ELSD), light absorption, fluorescence, refractive index (RI), flame 
ionization (FID) and mass spectrometry (MS). ELSD is the most commonly used detector 
for the analysis of phospholipids because of its compatibility with wide ranges of eluents 
and is uniform in response (Van der Meeren & Vanderdeelen, 2000). However, normal 
phase HPLC with a Charged Aerosol Detector (CAD) was used to analyze and quantify 
phospholipids. In recent years, a new type of detector, a CAD, was developed that 
involved the nebulization HPLC silica column effluent, evaporation of solvents, charging 
aerosol particulates and measurements of the aerosol current (Moreau, 2006). The CAD 
is capable of detecting common lipids in dairy, making it a valuable tool for quantitative 
HPLC analysis. In addition, the use of the CAD is advantageous because of its low 
minimum detection limits and linear mass-to-peak area relationship for various types of 
fats (Moreau, 2006).  
For this project, the phospholipid analysis via HPLC was performed using 
methods described by Rombaut et al. (2005). This HPLC method uses a gradient of 
26 
 
chloroform, methanol , and formic acid buffer with triethylamine at pH 3 to resolve the 
five classes of phospholipids in less than 21 minutes and extends the life of the silica 
column to over 1500 runs (Rombaut, Camp, & Dewettinck, 2005) (Rombaut & 
Dewettinck, 2006).  
2.6.3 Protein Analysis  
There are many techniques used in the dairy industry for protein determination. 
The Kjeldahl method, which is an AOAC standard for measuring protein, is one 
technique that digests and breaks down organic nitrogen compounds using concentrated 
sulfuric acid (H2SO4) in the presence of a catalyst, into ammonium (NH4
+
), titrated, and 
calculated using a conversion factor to give crude protein content (Tremblay, Laporte, 
Leonil, Dupont, & Paquin, 2003).  However, this technique uses highly-corrosive 
reagents and is very time consuming. The bicinchoninic acid (BCA) assay was invented 
by Paul Smith from the Pierce Chemical Company. The BCA assay is defined as a 
colorimetric detection that is used to determine the concentration of protein in a sample 
(Bainor, Chang, McQuade, Webb, & Gestwicki, 2011). This technique measures the 
reduction of Cu
2+
 (cuprous) to Cu
1+
 (cupric) using BCA, forming a purple-colored 
reaction (Olson & Markwell, 2007). The absorbance is then measured at 563 nm and is 
compared to a standard curve for concentration determination. The BCA assay was used 
in this project to initially determine the protein concentration of WPI, SBM, and WBM 
powders. This method was used over other protein determination methods because it is 
capable of producing better results with samples containing complex protein mixtures 
(Olson & Markwell, 2007).  
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Many proteins interact with each other through naturally occurring intermolecular 
disulfide bonds. These bonds can be broken down and studied using sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Milk and MFGM protein 
composition is usually examined with 8% acrylamide SDS-PAGE under reducing 
conditions (Zamora, Ferragut, Guamis, & Trujillo, 2012). However, caseins and whey 
proteins rapidly run out of the 8% gels since they are low in molecular weight (Zamora, 
Ferragut, Guamis, & Trujillo, 2012). Therefore, 15% acrylamide SDS resolving gels are 
now commonly used to study the proteins with Coomassie Blue staining (Singh, 2006). 
In this thesis, 15% acrylamide SDS-PAGE were performed on each prepared sample to 
determine whether or not protein aggregation was effected by the treatment given.  
2.7 Justification for Present Research 
According to the USDA, Americans do not consume enough dairy products and 
are, on average, gradually drinking less fluid milk now than in the 1970s for all age 
groups (Figure 2.9) (Stewart, Dong, & Carlson, 2013). Milk is one of the most nutritious 
products that nature has provided. This continuous decline in fluid milk consumption 
may lead to potential health implications since many consumers may not know and 
understand its nutritional value (Stewart, Dong, & Carlson, 2013).  
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Figure 2.9. Daily fluid milk consumption per capita in the United States (Stewart, Dong, 
& Carlson, 2013). Whole milk refers to milk containing ≥3.25% fat and lower fat milk 
refers to 2%, 1%, and skim milks.   
In contrast, the per capita consumption of dry buttermilk in the United States has 
been on the rise since 2005 (Figure 2.10) (USDA, 2012). Buttermilk is a nutritious dairy 
ingredient that comes from butter manufacturing. Buttermilk is a great source for MFGM 
constituents because it is enriched in phospholipids and proteins. It is also widely used in 
the food industry for its compositional and functional attributes, such as protein 
solubility, emulsifying capacity, viscosity, and foaming properties (Sodini, Morin, Olabi, 
& Jimenez-Flores, 2006). MFGM components not only offer functional properties but 
also contribute to health benefits as well. Phospholipids derived from the MFGM can be 
utilized as vehicles for bioactive components and nutrients for food and nutraceutical 
applications.  
Year 
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Figure 2.10. Annual dry buttermilk consumption (pounds) per capita in the United States 
(USDA, 2012) 
The purpose of this thesis is to study and compare the composition and structure 
of liposomal aggregates made from the phospholipids of commercial sweet buttermilk 
and whey buttermilk, prepared by microfluidization and homogenization. Particle size of 
the liposomal aggregates was investigated using a laser diffraction particle size analyzer. 
Advanced HPLC methodologies were applied to determine phospholipid concentration of 
the aggregates using a CAD in the buttermilk samples. Lastly, protein content was 
determined using SDS-PAGE in the liposomal aggregated samples. This thesis 
contributes to the foundation of understanding MFGM components, particularly 
phospholipids, in order to utilize them in future applications.    
0.00 
0.10 
0.20 
0.30 
0.40 
P
o
u
n
d
s 
 
Year 
30 
 
3.0 Materials and Methods 
3.1 Powders 
 In this research, three dairy ingredients were used to study the effects of high 
shear on liposomal aggregates. Commercial sweet cream buttermilk (SBM) powder was 
obtained from Grassland Dairy Products Inc. (Lot# 02012581202, Greenwood, WI, 
USA). Hilmar™ 9000 Whey Protein Isolate (WPI) powder was obtained from Hilmar 
Ingredients (Lot# 12145, Hilmar, CA, USA). Whey buttermilk (WBM) powder was 
manufactured at Cal Poly from pasteurized whey cream (Hilmar Cheese Company, 
Hilmar, CA, USA), which was derived from cheese processing. The whey cream was 
processed by methods described by Costa et al. (2010). Whey cream was churned into 
butter using a rotary churn system (Blentech Corporation, Santa Rosa, CA, USA) and 
placed through a cream separator to remove any residual butter. The buttermilk was 
concentrated using a pilot plant scale, GEA-Niro R12 Membrane Filtration unit (Hudson, 
WI, USA). Ultrafiltration (UF) was carried out 4 times and diafiltration (DF) was carried 
out twice to remove any caseins, lactose, minerals and water. The concentrated whey 
buttermilk was spray-dried into powder and processed using supercritical fluid extraction 
(SFE) (Thar Designs, Inc., Pittsburgh, PA, USA) to remove non-polar lipids. The finished 
product was placed into sterile storage bags and stored in the refrigerator at 10 ºC until 
needed.  
31 
 
3.2 Microfluidization: Sample Preparation, Treatments and Sample Collection 
3.2.1 Sample Preparation 
Samples are standardized to 2% (w/v) protein content by reconstituting WPI 
(2.8845 g/300 mL), SBM (2.5510 g/300 mL) and WBM powders (2.7574g/300 mL). 
Figure 3.1 illustrates the process flow of preparing samples. Each powder was rehydrated 
with room temperature deionized water in 600 mL Pyrex® beakers and agitated with a 1 
inch stir bar on a stir plate (Corning PC-620D, USA) at 360 rpm for 1 hour at room 
temperature (21.0 ± 1.03 ºC). The pH of the solutions were adjusted to 4.60 using 0.1 or 1 
N HCl (SA48-1, Fisher Scientific, Fair Lawn, NJ, USA) and to 6.80 using 0.1 or 1 N 
NaOH (SS266-4, Fisher Scientific, Fair Lawn, NJ, USA) using a pH meter (Thermo 
Scientific Orion® Model 410A+, USA) and reference electrode (Thermo Scientific 
Orion® 9157BN, USA). Each solution was heated to 70 ºC using a hotplate (Corning PC-
620D, USA) for 10 minutes with agitation at 360 rpm. The temperature of the solutions 
were monitored and read with a digital thermometer (Control Company Traceable®, 
Friendswood, TX, USA). The solutions were removed from the heat and allowed to cool 
to room temperature. Once cooled, the pH of the solutions were read and readjusted to 
4.60 and 6.80 as needed. 
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Figure 3.1. Sample Preparation for Microfluidization. 
3.2.2 Microfluidization Treatment and Sample Collection 
The reconstituted solutions at room temperature were passed through a bench top 
scale microfluidizer (Avestin, Inc., model EmulsiFlex™ - C5, Ottawa, Canada) (Figure 
3.2) at 2000 psi for a total of 3 passes. The first and last 10-15 milliliters of each sample 
were discarded to prevent sample dilution from any residual fluid left within the lines 
from cleaning and processing. The temperature of each sample was measured and 
recorded before and after each pass through the microfluidizer. The microfluidizer 
sample cylinder was rinsed and cleaned 5 times with deionized water before and after 
each sample. Samples were collected in 15 and 50 mL Falcon® Bluemax
TM
 
polypropylene conical tubes (Becton Dickson Labware, Franklin Lakes, NJ, USA) for 
analysis before and after each pass for a total of 3 passes. The 15 mL Falcon® tubes were 
stored in the refrigerator at 10 °C for particle size analysis and the 50 mL Falcon® tubes 
were stored in the freezer at -30 °C for phospholipid and protein analysis. 
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Figure 3.2. Avestin EmusliFlex™-C5 microfluidizer unit. A) sample cylinder; B) air 
motor; C) pressure gauge; D) interaction chamber; E) air pressure gauges from source. 
3.3 Homogenization: Sample Preparation, Treatments and Sample Collection 
3.3.1 Sample Preparation  
For pilot-plant scale, 2% protein (w/v) solutions were made by reconstituting WPI 
(28.8450 g/3 L), SBM (25.5099 g/3 L) and WBM powders (27.5736 g/3 L). Each powder 
was rehydrated with room temperature deionized water and mixed together using a 
commercial blender (Waring MX1000, Torrington, CT, USA) on low speed for 1 minute 
and high speed for 10 seconds. Each rehydrated solution was placed in a 6 L container 
and the pH was adjusted to 4.60 and 6.80 using a pH meter. Each solution was transferred 
to a 1 gallon stainless steel pot and heated over a kitchen stove top on high heat to 70 ºC 
for 10 minutes with continuous stirring using a wired whisk. The rehydrated mixtures 
were removed from the heat, transferred into clean 6 L containers, and allowed to cool to 
room temperature. The pH of each dairy ingredient was read and readjusted to 4.60 and 
6.80 as needed. 
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3.3.2 Homogenization Treatment and Sample Collection 
The reconstituted powders were homogenized at 2000 psi/500 psi using a pilot 
plant scale homogenizer (PMS Processing Machinery & Supply Co., Philadelphia, PA, 
USA) (Figure 3.3) at room temperature. The first and last 500 mL of each sample were 
discarded to prevent sample contamination from any residual fluid left within the lines 
from cleaning and processing. The temperature of each sample was measured and 
recorded before and after homogenization. The homogenizer sample cylinder was rinsed 
and cleaned 5 times with water before and after each sample. Samples were collected 
before and after homogenization in 15 and 50 mL Falcon® tubes for analysis. The 15 mL 
Falcon® tubes were stored in the refrigerator at 10 °C for particle size analysis and the 50 
mL Falcon® tubes were stored in the freezer at -30 °C for phospholipid and protein 
analysis. 
 
Figure 3.3. Pilot plant scale homogenizer. 
Inlet 
Outlet 
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3.4 Physical Properties of Liposomal Aggregates 
3.4.1 Particle Size Distribution  
The particle diameters (µm) of all WPI, SBM and WBM samples were 
determined according to a method described by Menard et al. (2010) using a laser 
diffraction particle size analyzer (Beckman Coulter, model LS 230 Fluid Module, CA). 
The fluid chamber was filled with 1 liter of room temperature deionized water. Before 
analysis, 16 mL of 35 mM EDTA/NaOH pH 6.8 buffer (99+% disodium salt dehydrate, 
Sigma) was added to the fluid chamber and allowed to adjust for electrical offsets and 
laser alignments prior to background measurements. Offsets and background were 
measured for 30 and 60 seconds, respectively. The fluid module was sonicated for 15 
seconds before each runtime. The runtime was measured for 60 seconds with a pump 
speed of 51 and sample loading measurements were maintained at 10% obscuration. 
Samples with an obscuration rate less than 3% were considered soluble and 
measurements were not taken for those samples.  
The standard mean diameters, in Number % mode, were calculated by the 
Beckman Coulter LS Software v. 3.29, and all measurements were performed in 
triplicate. The arithmetic mean diameter (d1, 0) is defined by Equation 1 as: 
       
     
 
     
    
           (Eq. 1) 
Where ni is the number of aggregate particles of diameter (di). 
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3.5 Chemical Composition  
3.5.1 Fat Extraction by Mojonnier Method  
Fat was extracted from WPI, SBM, and WBM powders, as well as the 3rd pass of 
the microfluidized and after homogenization of SBM and WBM pellets at pH 4.60 using 
the AOAC International modified Mojonnier method (989.05, 1996). All reagents used in 
this analysis were ACS grade from Fisher Scientific (Fair Lawn, NJ, USA). For WPI and 
buttermilk powders, 1 gram of powder was weighed into Mojonnier extraction flasks (# 
617600-0025, Kimbel/Kontes Glass, Vineland, NJ, USA) and diluted with 8.5 mL of 
deionized water at 38 ºC. The flasks were shaken for 30 seconds to thoroughly mix, and 
then tempered in a 38 ºC water bath for 30 minutes. To obtain the SBM and WBM 
pellets, 50 mL of both homogenized and microfluidized samples at pH 4.60 were 
centrifuged (Eppendorf Centrifuge 5810R, Germany) at 4000 rpm at 21 ºC for 10 
minutes. The supernatant was poured out and discarded. The pellets were collected and 
approximately 1 gram of each pellet was weighed out into Mojonnier extraction flasks. 
Each flask was diluted with 8.5 mL of deionized water at 38 ºC, shaken for 30 seconds to 
mix, and tempered in a 38 ºC water bath for 30 minutes.  
For the first fat extraction, 1.5 mL of ammonium hydroxide (A669-212) was 
added to each flask to neutralize acids and dissolve caseins (Figure 3.4). Three to five 
drops of 1% phenolphthalein solution (SP62-1) were added to the sample portion to 
differentiate between the organic and inorganic layers. Next, 10 mL of 95% denatured 
ethyl alcohol (A407-4) were added to each flask to prevent gelation, and then shaken 
vigorously by hand for 15 seconds. To each flask, 25 mL of ethyl ether (E199-4) were 
added to dissolve the lipids followed by the addition of 25 mL of petroleum ether (E120-
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4) to extract more lipids and remove any water from the organic layer. After each 
chemical addition, the Mojonnier flasks were vented to allow excess gas and pressure to 
escape. The flasks containing WPI, WBM, and SBM samples were centrifuged using a 
Garver Electrifuge 308M (Garver Manufacturing Inc., Union City, IN, USA) for 30 
seconds. The organic layer was decanted into pre-weighed aluminum tins, which were 
dehydrated at 100 °C for 1 hour and stored in a dessicator prior to use.  
 
Figure 3.4. Mojonnier fat extraction flow diagram. 
During the second extraction, 5 mL of 95% denatured ethyl alcohol were added 
and shaken for 15 seconds. Fifteen mL of ethyl ether and petroleum ether were 
consecutively added and shaken for 1 minute after each addition. The flasks were 
centrifuged for 30 seconds and decanted into respective aluminum tins. The organic layer 
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was evaporated on a 60 ºC hotplate and transferred into a 100 °C oven (Fisher Scientific, 
Isotemp Oven 750G, USA) for 30 minutes. The tins were transferred into a dessicator and 
allowed to cool to room temperature prior to weighing them. The fat samples were 
dissolved in 2 mL of HPLC grade hexane (H302-4) and stored in 4 mL amber vials 
(Fisher Scientific, USA) at -15 ºC for further analysis. 
3.5.2 Phospholipid Solid Phase Extraction (SPE) 
Phospholipids were extracted from the Mojonnier fat extracted samples by 
methods explained by Bitman et al. (1984). The reagents used for this analysis were of 
HPLC grade from Fisher Scientific (Fair Lawn, NJ, USA). The amber vials containing fat 
dissolved in hexane were removed from the freezer and allowed to come up to room 
temperature. Strata SI-1 Silica columns (2 g/12 mL, 55µm, 70A) were placed onto a 12-
postion SPE vacuum manifold system (Phenomenex, AH0-6023, USA) with 9 mL glass 
tubes positioned under each column. The silica cartridges were conditioned with 20 mL 
of chloroform (C606-4) and the extracted fat samples were loaded into the cartridges. The 
vials were washed with 1 mL of hexane to obtain residual lipids in the vial and added to 
the columns. The solvents and lipids were allowed to pass through the cartridge by 
gravity to enhance the retention of polar lipids. Neutral lipids were eluted from the fat 
samples with 40 mL of 1:1 (v/v) hexane:ethyl ether (309966, Sigma-Aldrich, St. Louis, 
MO, USA) and discarded. The 9 mL collection tubes were changed to clean ones to 
recover the polar lipid fraction. Polar lipids were eluted with 20 mL of methanol (A452-
4) to remove 80% of the phospholipids and the rest were eluted with 20 mL of 
chloroform. Figure 3.5 illustrates the process flow of the solid phase extraction. Each set 
of polar lipid fractions were pooled together and transferred into pre-weighed 50 mL 
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Pyrex® round bottom flasks (24/40, USA). The organic solvents were evaporated from 
each sample using a rotary evaporator (Labconco, Kansas City, MO, USA) connected to 
a pump (Cole-Palmer Instrument Company, MasterFlex Microprocessor Pump Drive, 
USA) in a 55 ºC water bath. To evaporate any residual water, the round bottom flasks 
containing the extracted polar lipids were wrapped in aluminum foil and flash-frozen 
with liquid nitrogen. The frozen round bottom flasks were freeze-dried under vacuum 
using a lyophilizer (Labconco, Freezone 4.5, USA) for 24 hours or until white 
phospholipid residues were observed. The dried phospholipids were weighed and 
dissolved in 2:1 (v/v) chloroform:methanol to make 2 or 5 mg/mL of phospholipids per 
sample. The recovered phospholipids were transferred into clean, 4 mL amber vials and 
stored in the freezer at -15 ºC until HPLC analysis.  
 
Figure 3.5. Solid phase extraction process flow diagram. 
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3.5.3 Phospholipid Profiling and Quantification by High Pressure Liquid 
Chromatography (HPLC)  
For phospholipid analysis, all reagents used were HPLC grade manufactured by 
Sigma-Aldrich (Germany) and Fisher Scientific (Fair Lawn, NJ, USA). The following 
pure polar lipids obtained from Sigma-Aldrich (Germany) were used as standards to 
identify lipids: 3-sn-Phosphatidylethanolamine (PE), L- Phosphatidylinositol (PI), 3-sn-
Phosphatidyl-L serine (PS), L--Phosphatidylcholine (PC), and N-Palmitoyl-D-
sphingomyelin (SM).  
 
Figure 3.6. Shimadzu Prominence HPLC unit with a CAD detector. A) degassing unit; 
B) pump; C) autosampler; D) communication bus module; E) column oven; F) CAD 
detector. 
Phospholipid separation of each sample was analyzed using HPLC according to 
methods described by Rombaut et al. (2005). A Prominence Ultra Flow Liquid 
Chromatography system (LC-20AB, Shimadzu) (Figure 3.6) with 2 solvent lines was 
used to carry out the phospholipid separations. The HPLC communication bus module 
(CBM-20A, Shimadzu) was a communication link between the HPLC equipment and a 
A 
B 
C 
D 
F 
E 
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computer output. The CBM was connected to an auto sampler (SIL-20A HT, Shimadzu), 
degasser (DGU-20A3, Shimadzu), pump (LC-20AB), column oven (CTO-20A, 
Shimadzu) and a Charge Aerosol Detection (CAD) detector (Corona Plus, Dionex, USA), 
where Nitrogen gas was used as a nebulizer at 35 psi. A 150 mm x 3 mm Prevail™ silica 
column with a 3 µm particle diameter (Part no. 99341, Grace Division, USA) and a 7.5 
mm x 3 mm Prevail™ guard silica column with a 5 µm particle diameter (Part no. 99354, 
USA) were equilibrated in the column oven at 40 ºC. Ten µL of sample were injected 
with the auto sampler for analysis. The elution of phospholipids were achieved using a 
linear gradient with 87.5:12:0.5 (v/v/v) chloroform:methanol:triethylamine (TEA) buffer 
(pH 3.0, 1 M formic acid) at t=0 minute to 28:60:12 (v/v/v) chloroform:methanol:TEA 
buffer at t=16 minutes (Rombaut et al., 2005). At t=17 minutes, the column was flushed 
and allowed to equilibrate at initial conditions prior to the next injection at t=28 minutes. 
The injection loop was rinsed with 2:1 (v/v) chloroform:methanol followed by an 
injection of the phospholipid standards after every 6
th
 sample and the flow rate was 
maintained at 0.5 mL/min.   
Phospholipid data was collected and quantified using the Shimadzu LC Solution 
software. Phospholipid peaks were identified by comparing the retention times of the 
pure phospholipid standards. The pure phospholipids were serially diluted (0.05 – 0.2 
mg/mL) with 2:1 (v/v) chloroform:methanol. Calibration curves were created from peak 
area values) and a linear regression equation (y = a + bx) was applied for each 
phospholipid. 
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3.6 Protein Composition 
3.6.1 Protein Quantification – Bicinchoninic Acid (BCA) Assay 
Pierce BCA™ Protein Assay Kit (#23252, Thermo Scientific, Rockford, IL, 
USA) was used to determine the initial protein concentration of WPI, SBM and WBM 
powders. A test tube standard protocol was followed according to the manufacturer’s 
instructions. A 5% (w/v) solution of each powder was made using room temperature 
deionized water. Dilutions of bovine serum albumin (BSA) standards were prepared per 
manufacture’s specifications with deionized water in 1.5 mL Eppendorf conical tubes. 
Working reagent was prepared by mixing 50 parts of Reagent A and 1 part of Reagent B. 
One hundred µL of each BSA standard dilutions and powder samples were pipetted into 
clean test tubes followed by a 2.0 mL addition of the working reagent. The test tubes 
were gently shaken to mix, incubated in a 37 ºC water bath for 30 minutes, and allowed 
to cool to room temperature. The absorbance for each sample was measured using a 
spectrophotometer (Molecular Devices, SpectraMax Plus, USA) set to 562 nm. To 
determine the protein concentration of WPI, SBM, and WBM, a standard curve was 
created with the average absorbance of the BSA standard vs. its concentration (µg/mL). 
All powder samples and standards were prepared and quantified in duplicate.  
3.6.2 Sodium Dodocyl-Sulfate Polyacrylamide Gel Electophoresis (SDS-PAGE) 
SDS-PAGE was performed on WPI, SBM, and WBM samples before and after 
homogenization and before and after the 3
rd
 pass of microfluidization under reducing and 
non-reducing conditions. SDS-PAGE equipments, regents, and prestained protein 
standards (161-0318, broad range) were of electrophoresis grade and obtained from 
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BioRad Laboratories, Inc. (Hercules, CA, USA). A 1:6 dilution of each sample was 
prepared with 2x Laemmli sample buffer (161-0737) in 1.5 mL Eppendorf tubes. Five 
percent of beta-mercaptoethanol (BP176-100, Fisher Scientific, Fair Lawn, NJ, USA) 
was added to the sample buffer for reducing conditions. The samples were heated at 95 
ºC for 4 minutes to break down proteins and allowed to cool to room temperature. 
Handcasted, 15% acrylamide SDS gels were prepared and mounted into an 
electrophoresis cell. The chambers of the cell were filled with 1x Tris-Glycine-SDS 
running buffer (161-0772). Fifteen µL of protein standard and sample were loaded into 
each individual well. The electrophoresis cell was connected to a power supply unit 
(PowerPAC 300) and the gels were run at a constant 200 V for 40-50 minutes or until the 
protein bands reached the bottom of the gels. The gels were washed with deionized water 
3 times prior to staining with Coomassie Brilliant Blue R-250 (161-0436). The gels were 
stained for about 6-8 hours at room temperature on a rotatory incubator (Max 2000 E-
class, Barnstead, IA, USA), rinsed 3 times with deionized water and destained with 
destaining solution. Prior to imaging, the gels were rinsed an additional 3 times with 
deionized water. The images were captured with a BioRad Imaging Universal Hood II in 
EPI white mode and analyzed with Quantity One 1-D Analysis software v4.6.3 for 
protein band quantification. The trace quantity (peak area x density in units of intensity x 
mm) parameter was used to compare the protein band intensities in each sample. 
3.7 Experimental Design 
The experimental design of this thesis consisted of 2 processing methods: 
microfluidization and homogenization. The microfluidization method was conducted 
using a 3x2x4 factorial in a randomized complete block design with a block on day (1, 2, 
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3, 4, and 5). The 3 treatment factors were milk powders (WPI, SBM, and WBM), pH (4.6 
and 6.8), and number of passes through the microfluidizer (0, 1, 2, and 3) with 24 
treatment combinations per day. The homogenization method was conducted using a 
3x2x2 factorial in a randomized complete block design with a block on day (1, 2, and 3). 
The 3 treatment factors were milk powders (WPI, SBM and WBM), pH (4.6 and 6.8), 
and time point (before and after) with 12 treatment combinations per day. Treatments 
were randomly assigned to the experimental unit using JMP Pro 9 (SAS Institute Inc.). 
All experiments were performed on different days for both processing methods. The 
responses were particle diameter (µm) from particle size analysis, concentration of 
phospholipids using HPLC, and trace quantity of protein band intensities by SDS-PAGE.  
The particle sizes for WPI and SBM samples were not measured during particle 
size analysis because they were soluble at pH 6.8. Therefore, the experimental design of 
this study was adjusted to one treatment factor with four levels: SBM at pH 4.6, WPI at 
pH 4.6, WBM at pH 4.6, and WBM at pH 6.8.   
3.8 Statistical Analysis 
All experiments were performed using a randomized complete block design with 
a block on days. Microfluidization and homogenization processes were used to produce 
liposomal aggregates. The treatment factors for microfluidization were milk powder-pH 
combination (WPI4.6, SBM4.6, WBM4.6, and WBM6.8), and number of passes (0, 1, 2, 
and 3). The treatment factors for homogenization were the same as for microfluidization 
except time point (before and after) replaced number of passes. Particle diameter was the 
response variable for the statistical analysis in this research. All ANOVA statistical 
analyses were carried out using JMP Pro 10. ANOVA F-tests for each analysis used a 5% 
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overall significant level. Each ANOVA term was checked using a Bonferroni adjusted 
1.67% individual significance level. Levels of significant terms were compared using a 
Tukey-Kramer multiple comparison test at the 1.67% significance level. Before and after 
particle sizes were compared using confidence intervals adjusted to 95% overall 
confidence (99.37% individual confidence).  
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4.0 Results and Discussion 
4.1 BCA Protein Assay 
The BCA Protein Assay was performed to determine the initial protein 
concentration of 5% (w/v) reconstituted solutions of WPI, SBM, and WBM powders 
prior to executing the experimental design. The absorbance was taken for each sample to 
determine the protein concentration using a bovine serum albumin (BSA) standard curve 
(Figure 4.1). The protein concentration of the WPI, SBM, and WBM solutions ranged 
from 10-13% with means of 10.4%, 11.8%, and 10.9%, respectively (Table 4.1). SBM 
showed higher protein content because it contained caseins. WPI and WBM are 
concentrated in whey proteins and contain little to no caseins. From this assay, 2% (w/v) 
protein solutions of WPI, SBM, and WBM were prepared for the execution of the 
experimental design to mimic the protein content in milk (Sodini, Morin, Olabi, & 
Jimenez-Flores, 2006). 
 
Figure 4.1. BSA standard curve of absorbance at 562 nm vs. concentration (mg/mL). R
2
 
= 0.957. 
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Table 4.1. BCA protein assay of 5% (w/v) reconstituted dairy powders. 
Repetition Sample 
Concentration 
(mg/mL) 
Protein  
(%) 
1 WPI 5.234 10.468 ± 0.00 
2 WPI 5.161 10.321 ± 0.00 
1 SBM 5.457 10.915 ± 0.00 
2 SBM 6.354 12.708 ± 0.00 
1 WBM 5.331 10.661 ± 0.00 
2 WBM 5.547 11.095 ± 0.00 
    
4.2 Physical Properties of Liposomal Aggregates 
4.2.1 Particle Size Analysis 
The particle size distribution was determined using the Beckman Coulter LS 230 
particle size analyzer for WPI, SBM, and WBM samples that underwent treatments. 
EDTA, a chelating agent, was used to disrupt and dissociate casein micelles by 
sequestering Ca
2+
 for particle stability (Menard, et al., 2010). The liposomal aggregate 
dispersions were analyzed using the number-weighted average diameter (d1, 0) as a 
function of particle diameter (µm). The particle size distribution resembled a Gaussian 
curve, which is in accordance with previous particle size studies (Menard, et al., 2010) 
(Sodini, Morin, Olabi, & Jimenez-Flores, 2006) (Nongonierma, Abrlova, Fenelson, & 
Kilcawley, 2009). Figure 4.2 represents the particle diameter distribution for 
microfluidized samples before and after each pass and Figure 4.3 represents the particle 
diameter distribution for homogenized samples. These plots illustrate that the particle size 
in each treated sample may have decreased in diameter with processing.  
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Figure 4.2. Particle Size Distribution of WPI, SBM, and WBM before and after each 
pass through the microfluidizer. (a) WPI at pH 4.60; (b) SBM at pH 4.60; (c) WBM at pH 
4.60 and 6.80.   
49 
 
 
Figure 4.3. Particle Size Distribution of WPI, SBM, and WBM before and after 
homogenization with 3 repetitions per treatment structure. (a) WPI at pH 4.60; (b) SBM 
at pH 4.60; (c) WBM at pH 4.60; (d) WBM at pH 6.80.   
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At pH 6.8, both WPI and SBM had an obscuration rate of less than 3% and were 
considered soluble. Their initial pH and standard deviations were 6.54 ± 0.283 and 7.32 ± 
0.072 respectively, whereas, WBM had an initial pH of 5.36 ± 0.076 prior to any 
conditioning. As described earlier, particle size measurements could not be taken on WPI 
and SBM samples at pH 6.8. In addition, WPI, SBM, and WBM samples were not 
randomized for the homogenization or microfluidization process, which would result in 
confounding effects if analyzed in this way. Randomization occurred when assigning 
treatments to the dairy solutions and on the day of the experiment to randomize the run 
order. Since there were values that were not determined for WPI and SBM at pH 6.8, the 
statistical analysis of comparing the before and after particle diameter after each pass of 
microfluidization or after homogenization could not be performed for all combinations of 
powder type and pH. Instead, a one factor ANOVA was performed using the before and 
after paired differences for the four remaining combinations of powder and pH. To 
analyze the effect between homogenization and microfluidization, the particle diameter 
of the 3
rd
 pass was taken to represent after processing for microfluidization. The particle 
diameter from the before (homogenization) or 0 pass (microfluidization) was subtracted 
from the after (homogenization) or 3
rd
 pass (microfluidization). The resulting paired 
differences represent the change in particle size prior to treatment and after treatment. A 
positive difference indicates that there was a decrease in particle diameter and the 
opposite holds true for any negative differences.  
The relationship between the particle size paired differences and the treatments of 
homogenized samples is strong with the model fitting the data well (R
2
 = 0.949). 
However, the normality and equal variance model assumptions are violated due to 
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outliers (Appendix C). WPI, SBM, and WBM samples resulted in significant particle 
diameter differences (p < 0.0001) from before to after homogenizing. SBM at pH 4.6 had 
a least squares mean (LSM) of 11.614 µm and an interval of 9.527 to 13.700 at 98.75% 
confidence (α = 0.0125) using the Bonferroni’s correction method to account for the 
number of treatment levels. This indicates that there is a large significant difference in 
particle diameter from before to after homogenizing (Table 4.2). WBM at pH 4.6 and pH 
6.8 had a LSM of 0.887 µm and 0.571 µm and a confidence interval between -1.200 to 
2.973 and -1.516 to 2.657, respectively. There is not enough evidence to detect that there 
is a significant change from before homogenization compared to after for WBM at either 
pH. WPI at pH 4.6 exhibited a LSM of 3.499 µm and a confidence interval between 
1.413 and 5.585. This shows that the change in particle diameter is relatively small, but is 
significantly different from before homogenization compared to after.  
Table 4.2. Least Square Means for Homogenized Samples. 
Treatment Level 
Least Sq 
Mean (µm) 
 Std Error Lower 98.75% CI Upper 98.75% CI 
SBM; pH 4.6
a
 11.614  0.645 9.527 13.700 
WPI; pH 4.6
b
 3.499  0.645 1.413 5.585 
WBM; pH 6.8
b
 0.887  0.645 -1.200 2.973 
WBM; pH 4.6
b
 0.571  0.645 -1.516 2.657 
a,b
 = Levels that are not connected by same letter are significantly different. 
 The microfluidization treatment resulted in the reduction of particle diameters 
after the first pass for SBM samples, which is in accordance with liposomal particle size 
studies performed using a microfluidizer (Thompson & Singh, 2006) (Nongonierma, 
Abrlova, Fenelson, & Kilcawley, 2009). The mean particle diameters for all treatments at 
every pass are shown in Table 4.3 from the SAS model analysis using an adjusted α = 
0.0167. There is a significant difference in the mean particle diameter between the treated 
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powders at a specific pH and the number of passes through the microfluidizer (p < 
0.0008), which indicates that there was an interaction effect between the treatment and 
number of passes. Prior to microfluidization, SBM at pH 4.6 had a mean particle 
diameter of 11.152 µm, which was the largest size compared to all other treatments at 
pass 0. There are significant differences in the mean particle diameter between SBM at 
pH 4.6 and WBM at pH 4.6 (p < 0.0002), WPI at pH 4.6 (p < 0.0002), and WBM at pH 
6.8 (p < 0.0045) at pass 0. This significance means that SBM at pH 4.6 at pass 0 had a 
mean particle diameter that is much larger than all other samples at pass 0. There are 
significant differences in the mean particle diameter between pass 0 and the other passes 
only for SBM at pH 4.6 (p < 0.0001). Changes in mean particle diameter after pass 1 
were smaller and not statistically significant. More replications may be needed to detect 
significant differences after more than 1 pass through the microfluidizer.  
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Table 4.3. Mean Particle Diameter for Microfluidized Samples. 
Treatment Pass # Mean Particle Diam. (µm) Standard Error 
SBM; pH 4.6
a
 0 11.152 0.821 
SBM; pH 4.6
b
 1 4.189 0.693 
SBM; pH 4.6
b
 2 3.315 0.403 
SBM; pH 4.6
b
 3 2.717 0.370 
WBM; pH 4.6
b
 0 2.880 0.821 
WBM; pH 4.6
b
 1 1.955 0.693 
WBM; pH 4.6
b
 2 1.479 0.403 
WBM; pH 4.6
b
 3 1.469 0.370 
WBM; pH 6.8
b
 0 2.925 0.821 
WBM; pH 6.8
b
 1 1.980 0.693 
WBM; pH 6.8
b
 2 1.871 0.403 
WBM; pH 6.8
b
 3 1.376 0.370 
WPI; pH 4.6
b
 0 4.995 0.821 
WPI; pH 4.6
b
 1 3.038 0.693 
WPI; pH 4.6
b
 2 2.585 0.403 
WPI; pH 4.6
b
 3 2.501 0.370 
a, b
 = Levels that are not connected by same letter are significantly different. 
 
A graphical representation of the mean particle diameters after each pass through 
the microfluidizer in all treatments is shown in Figure 4.4. From this plot, WBM at pH 
4.6 and 6.8 are almost identical in the mean particle size before and after each pass. WPI 
at pH 4.6 showed a slightly larger mean particle size than both WBM treatments, but the 
differences were statistically insignificant. However, there are significant differences 
between WPI at pH 4.6, SBM at pH 4.6, WBM at pH 4.6, and WBM at pH 6.8 at pass 0 
(p < 0.0001). 
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Figure 4.4. Mean particle diameter plot for microfluidized samples. 
In comparison of both methods of high shear processing, the particle size paired 
differences and the treated samples exhibited a strong relationship (R
2
 = 0.885) and 
normally distributed residuals. The equal variance assumption is violated due to large 
spreading of data and outliers (Appendix E). Some treated samples also resulted in 
significant particle diameter differences (p < 0.0001) from before to after homogenizing 
and microfluidizing. Homogenized and microfluidized SBM at pH 4.6 had intervals 
between 8.595 to 14.632 and 6.096 to 10.773, respectively, at Bonferroni adjusted 
99.37% confidence (α = 0.0063). This indicates that there is detectable significant 
difference in the mean particle diameter from before to after homogenizing and 
microfluidizing (Table 4.4). However, there is not enough evidence to identify a 
significant difference between the two processing methods. Homogenized WBM samples 
at pH 4.6 and pH 6.8 had a confidence interval between -2.448 to 3.589 and -2.132 to 
3.905, respectively. Microfluidized WBM samples at pH 4.6 and pH 6.8 had a confidence 
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interval between -0.927 to 3.749 and -0.789 to 3.887, respectively. This indicates that 
there is not enough evidence to detect a significant change from before processing 
compared to after at either pH in either processes. Homogenized and microfluidized WPI 
samples at pH 4.6 exhibited a confidence interval between 0.480 to 6.518 and 0.156 to 
4.832. This indicates that the change in particle diameter is very small, but is significantly 
different from before processing compared to after. Also, there were no detectable 
differences in processing techniques on the particle size change for any treatment.   
Table 4.4. Least Square Means for Homogenized and Microfluidized Samples. 
 Treatment Level 
Least Sq 
Mean (µm) 
 Std Error 
Lower 99.37% 
CI 
Upper 99.37% 
CI 
SBM; pH 4.6; Homog
a
 11.614  1.002 8.595 14.632 
SBM; pH 4.6; MF
a
 8.434  0.776 6.096 10.773 
WPI; pH 4.6; Homog
b
 3.499  1.002 0.480 6.518 
WPI; pH 4.6; MF
b
 2.494  0.776 0.156 4.832 
WBM; pH 6.8; MF
b
 1.549  0.776 -0.789 3.887 
WBM; pH 4.6; MF
b
 1.411  0.776 -0.927 3.749 
WBM; pH 6.8;Homog
b
 0.887  1.002 -2.132 3.905 
WBM; pH 4.6; Homog
b
 0.571  1.002 -2.448 3.589 
a,b
 = Levels that are not connected by same letter are significantly different. 
Abbreviations: Homog = Homogenization; MF = Microfluidization. 
 
In summary, WBM and WPI contain the smallest change in particle size in both 
processes at either pH. All WBM and WPI samples had significantly smaller change in 
particle size than SBM. The particle size of WBM did not change significantly during 
either process. Although WBM particle size did not change significantly, it is still an 
important factor in this study because its size and structure may possibly be influenced by 
the presence of phospholipids. WBM is a nutritious ingredient that is comprised of 
MFGM constituents and is more saturated in phospholipids than SBM and may 
contribute to its small size. In a study by Sodini and colleagues (2006), WBM also 
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exhibited smaller mean particle size compared to various types of sweet buttermilks and 
whey powder at various pH. They found that there were no significant differences 
between WBM at initial pH and at pH 4.0.  
In this project, SBM was found to have the largest particle size and mean 
difference in both processes at pH 4.6. This is possibly due to caseins and whey proteins 
intermolecularly interacting with each other via disulfide and hydrogen bonding while 
being adsorbed onto the surface of liposomes forming large aggregates when treated with 
high shear. From the results above, WPI and WBM were not significantly different from 
each other given the processing and pH treatments. They both exhibited similar mean 
particle size trends suggesting that they share common characteristics since they consist 
of the same materials. One of the main differences between WPI and WBM are the 
presence of phospholipids in WBM which could possibly contribute to its small structure.  
4.2.2 Confirmation with Confocal Microscopy 
Confocal microscopy was utilized in this project to capture the presence of the 
aggregates and explore their structures. These images are represented in Figure 4.5 at the 
various treatments and conditions. Protein structures were stained green and 
phospholipids were stained red. These images were taken to validate the presence of 
aggregates, in which are the specks of color within the images, and confirm what the 
particle size analyzer is detecting. 
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WPI; pH 6.8; No treatment 
 
SBM; pH 6.8; No treatment 
 
WBM; pH 6.8; No treatment 
 
 
  
WPI; pH 4.6; Homog. 
 
SBM; pH 4.6; Homog. 
 
WBM; pH 4.6; Homog. 
 
 
  
WPI; pH 4.6; MF 
 
SBM; pH 4.6; MF 
 
WBM; pH 4.6; MF
Figure 4.5. Confocal images of WPI, SBM, and WBM at various conditions.  
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4.3 Chemical Composition 
4.3.1 Fat Extraction by Mojonnier Method 
 Fat was extracted from samples obtained after homogenization and after the 3
rd
 
pass of microfluidization using the standard Mojonnier ether method. Due to the 
complexity of the experimental design, analyses of all samples collected in this study 
were not executed in full. Instead, specific homogenized and microfluidized samples 
were chosen across all repetitions for fat extraction to explore how processing and pH 
might influence phospholipid ratios. Fat was also extracted from WPI, SBM, and WBM 
powders and used as a reference in this project. Samples that were treated at pH 4.6 
resulted in the precipitation, or sedimentation, of liposomal aggregates. The precipitated 
samples were centrifuged to obtain the aggregates in pellet form. Figure 4.6 illustrates 
samples at pH 4.6 with pellets and at pH 6.8 without pellets. Fat was also extracted from 
the WBM and SBM supernatants at pH 4.6. 
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Figure 4.6. Images of WPI, WBM, and SBM samples after microfluidization. (a) WPI at 
pH 6.8; (b) WPI at pH 4.6; (c) WBM at pH 6.8; (d) WBM at pH 4.6; (e) SBM at pH 6.8; 
(f) SBM at pH 4.6. 
Unprocessed WPI powder resulted in an average of 0.179% total fat per 1 gram of 
powder (Table 4.5). Since this product contains very little fat, all WPI treated samples 
were excluded from further fat analysis. Homogenized and microfluidized WBM and 
SBM at pH 6.8 did not precipitate because they were soluble. For that reason, fat was 
extracted from the samples as they were without centrifugation and resulted in fat content 
of 0.254% and less than 0.1%, respectively, per 10 grams of fluid. The extracted 
supernatant of homogenized and microfluidized WBM and SBM samples at pH 4.6 also 
had a fat content of less than 0.1% per 10 grams of fluid. This information suggests that 
there were residual lipids that can be found in the supernatant of precipitated liposomal 
aggregates.  The magnitude of the total fat content in these samples was not sufficient to 
extract and measure phospholipid content. Figure 4.7 best illustrates the insignificant 
amount of total fat in WPI, supernatant of WBM and SBM at pH 4.6, and WBM and 
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SBM at pH 6.8 per repetition. Thus, samples that contain less than 1% total fat were 
excluded from further lipid analysis. 
Table 4.5. Fat content of WPI, SBM, and WBM by Mojonnier Extraction.  
 
Fat % per 1 g solid or 10 g fluid 
Sample 
Days 
Avg. (%) 
1 2 3 
WPI; no treatment* 0.165 0.194 ND 0.179 
WBM; no treatment* 27.375 27.426 ND 27.400 
WBMSN; pH 4.6; MF** -0.017 0.021 ND 0.002 
WBMP; pH 4.6; MF* 8.451 10.101 8.540 9.031 
WBM; pH 6.8; MF** 0.220 0.284 0.256 0.254 
WBMP; pH 4.6; Homog* 10.968 9.899 9.269 10.045 
WBM; pH 6.8; Homog** 0.256 0.220 0.202 0.226 
SBM; no treatment* 8.989 8.835 ND 8.912 
SBMSN; pH 4.6; MF** -0.024 0.019 ND -0.003 
SBMP; pH 4.6; MF* 0.348 5.486 4.379 3.404 
SBM; pH 6.8; MF** 0.032 0.091 0.059 0.061 
SBMP; pH 4.6; Homog* 3.893 4.131 3.954 3.993 
SBM; pH 6.8; Homog** 0.115 0.042 -0.025 0.044 
* Solid product; ** Fluid product. ND = Not determined. 
 
 
Figure 4.7. Percentage of total fat (% per 1 g solid or 10 g fluid)  in WPI, WBM, and 
SBM under various conditions per day. 
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Untreated WBM powder contained about 27.4% total fat per 1 gram of powder, 
while processed WBM pellets at pH 4.6 contained about 9-10% per approximately 1 
gram of solid (pellet). Untreated SBM powder contained 8.9% fat per 1 gram of powder, 
while homogenized and microfluidized SBM pellets contained about 3-4% total fat per 
approximately 1 gram of solid. WBM is comprised of higher fat content because it has 
been concentrated through membrane ultrafiltration (Costa, Elias-Argote, Jimenez-Flores, 
& Gigante, 2010). Since SBM was not processed and concentrated further, it contains 
less fat than WBM. WPI is manufactured through the use of membrane filtration and can 
contain residual lipids. The extracted 0.179% total lipids from WPI represent the residual 
lipids that were left behind in the product post manufacture.  
4.3.2 Phospholipid Solid Phase Extraction (SPE) 
Next, solid phase extraction was performed on the Mojonnier fat extracted 
samples to purify polar phospholipids utilizing methods described by Bitman et al (1984). 
Non-polar lipids were eluted by gravity with 1:1 (v/v) hexane:diethyl ether using silica-
based cartridges, and polar lipids were eluted with equal volumes of methanol and 
chloroform. The chloroform and methanol organic phase of all phospholipid extracted 
samples were evaporated off with a rotary evaporator and then freeze dried for 24 hours 
to remove any residual water.  
The untreated WPI powder contained about 0.254% phospholipids per 1 gram of 
powder (Table 4.6), which is not consistent with the untreated WPI powder that had a 
total fat content of 0.179%, as previously mentioned. This could be due to human and 
equipment errors when weighing the phospholipid crude, or dust particles may have 
entered the sample after SPE, evaporation, and/or freeze drying. Untreated WBM powder 
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contained about 1.67% phospholipids per 1 gram of powder, while homogenized and 
microfluidized WBM pellets at pH 4.6 contained 0.63% and 0.32% per approximately 1 
gram of solid, correspondingly. Untreated SBM powder contained about 1.10% 
phospholipids per 1 gram of powder, while homogenized and microfluidized SBM pellets 
at pH 4.6 contained 0.29% and 0.67% phospholipids per approximately 1 gram of solid.   
Table 4.6. Phospholipid concentration (%) of WPI, SBM, and WBM by SPE. 
 
Phospholipid (%) per 1 g solid 
Sample 
Day 
Avg. (%) 
1 2 3 
WPI; no treatment 0.289 0.219 ND 0.254 
WBM; no treatment 1.577 1.755 ND 1.666 
WBMP; pH 4.6; MF 0.360 0.282 0.306 0.316 
WBMP; pH 4.6; Homog 0.678 0.499 0.703 0.627 
SBM; no treatment 0.996 1.196 ND 1.096 
SBMP; pH 4.6; MF 0.074 0.450 0.345 0.290 
SBMP; pH 4.6; Homog 0.331 0.832 0.847 0.670 
ND = Not determined. 
 Untreated WBM and SBM powder both consists of approximately 1%-2% 
phospholipid content, which is in accordance with literature (Fox & McSweeney, 1998) 
(Keenan, Mather, & Dylewski, 1988). Homogenized and microfluidized WBM and SBM 
pellets all resulted in lower amounts of phospholipid content because the samples were 
diluted to create 2% (w/v) protein solutions. Figure 4.8 best illustrates the phospholipid 
concentration in each sample per repetition. In addition, only 50 mL of sample was 
collected per treatment combination for lipid analysis, while the rest were use in particle 
size and protein analysis or discarded in excess. Theoretically, if total lipids were 
extracted from the entire final volume of the processed and treated samples at either pH, 
regardless of processing techniques, the phospholipid concentration should essentially 
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make up approximately 1% of the total fat. Microfluidized WBM and SBM pellets at pH 
4.6 resulted in lower concentrations of phospholipids than homogenized samples due to 
structural changes to the aggregates during treatments with high shear. Structural 
alterations took place during induction of high shear causing proteins to surround the 
phospholipids. The protein layer acts as a protective coat making phospholipid extraction 
difficult to fully obtain phospholipids from the treated samples.  
 
Figure 4.8. Percentage of phospholipids (% per 1 g solid) in WPI, WBM pellets 
(WBMP), and SBM pellets (SBMP) at pH 4.6 per day. MF = Microfluidization and 
Homog = Homogenization. 
4.3.3 Phospholipid Profiling and Quantification by HPLC 
Lastly, the extracted phospholipid samples were analyzed using HPLC in order to 
determine concentrations of the polar phospholipid classes. The phospholipid crude were 
diluted to 2 mg/mL in 2:1 (v/v) chloroform:methanol and stored in a freezer prior to 
analysis. It is important to investigate and quantify the various phospholipid classes 
because they are considered as bioactive compounds, which are responsible for providing 
structure to the milk fat membrane or liposomal aggregates, and contribute great 
nutritional value (Menard, et al., 2010).  
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To determine the concentration of phospholipid classes in each sample, five 
standard calibration curves were created with serially diluted phospholipid standards. The 
calibration curves were graphed as a function of phospholipid peak area. The peak areas 
for each of the phospholipid classes were manually integrated from chromatogram 
outputs at their respective retention times using the Shimazu LC Solutions software. 
Calculations were then carried out using the appropriate linear equation (Table 4.7). 
HPLC analysis occurred over three consecutive days, in which are independent of and not 
related to the days of the experimental design. Standards were run each day, prior to 
sample analysis, to achieve accurate readings.  
Table 4.7. Linear equations of phospholipid standards and their respective retention time. 
Day 
Phospholipid 
Class 
Retention 
Time (min) 
Linear Equation* R
2
 
1 PE 7.484 PEconc = 9.880x10
-8 
* Peak Area - 0.016 0.995 
1 PI 8.438 PIconc = 3.991x10
-8
 * Peak Area - 0.046 0.989 
1 PS 9.036 PSconc =6.604x10
-8
* Peak Area - 0.019 0.980 
1 PC 9.847 PCconc =3.275x10
-8 
* Peak Area - 0.021 0.989 
1 SM 11.896 SMconc =3.920x10
-8 
* Peak Area - 0.016 0.958 
2 PE 7.456 PEconc =8.332x10
-8
 * Peak Area - 0.001 0.996 
2 PI 8.381 PIconc =3.167x10
-8
 * Peak Area - 0.028 0.999 
2 PS 9.033 PSconc =5.381x10
-8
 * Peak Area - 0.008 0.997 
2 PC 9.992 PCconc =2.81x10
-8
 * Peak Area - 0.019 0.995 
2 SM 12.107 SMconc =2.964x10
-8
 * Peak Area - 0.011 0.999 
3 PE 7.452 PEconc =6.019x10
-8
 * Peak Area - 0.013 0.996 
3 PI 8.378 PIconc =2.413x10
-8
 * Peak Area - 0.031 0.998 
3 PS 9.102 PSconc =4.225x10
-8
 * Peak Area - 0.015 0.997 
3 PC 10.091 PCconc =2.196x10
-8
 * Peak Area - 0.019 0.997 
3 SM 12.212 SMconc =2.172x10
-8
 * Peak Area - 0.007 0.999 
* All standard curves are in Appendix F. 
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 The untreated WPI powder samples did not result in any phospholipid content 
after HPLC analysis, as shown in Figure 4.9. In Table 4.8, WPI samples consisted of 0% 
PE, and negative percentages for PI, PS, PC, and SM on average. The negative 
percentages correspond to the lack of peaks. Negative values occur when peak areas are 
integrated below baseline. The negative values represent no presence of phospholipids 
and resulted in negative numbers due to human errors when visually identifying peaks. 
Figure 4.10 shows a representational chromatogram overlay of WPI powder in 
comparison to WBM and SBM powder, phospholipid standards, and 2:1 (v/v) 
chloroform:methanol as baseline. In this figure, WPI is illustrated as the first 
chromatogram (1), which does not show any peaks or any presence of phospholipids. 
These results do not correlate with the 0.254% average phospholipid concentration 
obtained by the SPE method. It is possible that the concentration of phospholipids within 
the WPI samples were so small that the CAD was not able to detect its presence during 
analysis. 
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Figure 4.9. Average concentration of Phospholipid classes (mg/mL per 1000 mg solid). 
 
Figure 4.10. HPLC Chromatogram of phospholipids extracted from WPI, WBM, and 
SBM powder. 1. WPI powder; 2. WBM powder; 3. SBM powder; 4. Phospholipid 
standards (0.1 mg/mL); 5. 2:1 (v/v) Chloroform: Methanol (Baseline). Phospholipid 
peaks: PE = Phosphatidylethanolamine; PI = Phosphatidylinositol; PS = 
Phosphatidylserine; PC = Phosphatidylcholine; SM = Sphingomyelin. 
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Table 4.8. Average percentage of phospholipid content in fat globules. 
 
Average percent (%) per total mg phospholipids 
Phospholipid 
Class 
Dry Powder 
 
Microfluidization 
 
Homogenization 
No Treatment 
 
pH 4.6 
 
pH 4.6 
WPI WBM SBM 
 
WBMP SBMP 
 
WBMP SBMP 
PE 0.000 13.329 6.573 
 
30.260 14.380 
 
15.052 4.521 
PI -1.157 0.898 0.991 
 
-0.040 1.569 
 
-0.435 -0.419 
PS -0.275 1.760 2.423 
 
-0.100 0.000 
 
-0.084 -0.248 
PC -0.353 2.820 2.355 
 
2.770 7.686 
 
2.273 0.983 
SM -0.196 1.347 0.414 
 
0.000 2.490 
 
0.019 -0.111 
Total PL (mg) 2.550 16.700 11.000 
 
3.333 5.133 
 
1.700 3.900 
 
 
As mentioned previously, WBM powder that was untreated contained the highest 
phospholipid concentration compared to SBM powder and this is reflected in the HPLC 
results. Figure 4.11 is a visual representation of Table 4.8. WBM and SBM powder both 
contained the five phospholipid classes with PE being the majority of the phospholipid in 
each sample. Figure 4.10 illustrates and Table 4.8 confirms that WBM powder contains 
about 1% SM of the total phospholipid content and SBM powder contains less than 0.5%. 
WBM and SBM powders both contain about the same concentration of PI and PC, 
0.90%-0.99% and 2.36%-2.84% of the total phospholipid content, respectively. However, 
SBM powder contains 2.42% PS, while WBM contains only about 1.76%.  
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Figure 4.11. Average percentage of phospholipid classes in relation to total mg of 
phospholipids in each sample.  
According to Figure 4.9 and Figure 4.11, Homogenized SBM pellet at pH 4.6 
resulted in less phospholipid content within the polar classes than the microfluidized 
SBM pellet. Similarly, homogenized WBM pellets at pH 4.6 also exhibited lower 
phospholipid content within each class. Figure 4.12 shows chromatogram overlays of 
SBM samples and Figure 4.13 shows overlays of WBM samples. Both figures are in 
accordance with Figure 4.9 and Figure 4.11 above. Table 4.8 shows that microfluidized 
WBM and SBM pellets had a higher total phospholipid yield than homogenized samples. 
Microfluidized WBM pellets at pH 4.6 yield an average of 3.33 mg total phospholipids, 
whereas homogenized WBM pellet samples only yield about 1.7 mg total. Microfluidized 
SBM pellet samples contained about 5.13 mg total phospholipids, while homogenized 
SBM pellets contained 3.90 mg total phospholipids. This difference in total phospholipid 
yield may be due to dilutions of the sample during treatment. As mentioned previously, if 
the entire volume of samples collected were analyzed, the amount of total phospholipids 
would be similar.  
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There are many factors that may also contribute to changes in the phospholipid 
profile. According to Keenan (1983), homogenization does not alter the phospholipid 
ratios in MFGM and skim milk. Across all homogenized and microfluidized samples, PE 
and PC remained present, even after treatment and extraction procedures. However, the 
presence of PI, PS, and SM in these samples were either very low or could not be 
detected. A study by Gallier and colleagues (2010) suggest that thermal treatment during 
pasteurization is responsible for the different profiling of phospholipids in milk. These 
differences in phospholipid profiling may possibly be due to the initial thermal treatment 
to 70 ºC to denature the whey proteins for aggregation. Alternatively, these changes in 
phospholipid profiling may be also due to protein interactions during processing (i.e. 
homogenization or microfluidization) causing structural changes to take place. Whey 
proteins can interact with caseins by disulfide and hydrophobic interactions, forming 
aggregates that are adsorbed onto the MFGM (Brown, 1988) (Ye, Anema, & Singh, 
2008). β-Lg and α-La can also interact with each other to form aggregates that are 
adsorbed on the membrane (Fox & McSweeney, 1998). Perhaps these protein interactions 
with the MFGM altered the aggregate structure and limited phospholipid extraction using 
the extraction methods used causing difference in phospholipid profiling.   
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Figure 4.12. HPLC Chromatogram of phospholipids extracted from SBM. 1. SBM Pellet 
from Microfluidization at pH 4.60; 2. SBM Pellet from Homogenization at pH 4.60; 3. 
SBM powder; 4. Phospholipid standards (0.1 mg/mL); 5. 2:1 (v/v) Chloroform: Methanol 
(Baseline). Phospholipid peaks: PE = Phosphatidylethanolamine; PI = 
Phosphatidylinositol; PS = Phosphatidylserine; PC = Phosphatidylcholine; SM = 
Sphingomyelin.  
 
Figure 4.13. HPLC Chromatogram of phospholipids extracted from WBM. 1. WBM 
Pellet from Microfluidization at pH 4.60; 2. WBM Pellet from Homogenization at pH 
4.60; 3. WBM powder; 4. Phospholipid standards (0.1 mg/mL); 5. 2:1 (v/v) Chloroform: 
Methanol (Baseline). Phospholipid peaks: PE = Phosphatidylethanolamine; PI = 
Phosphatidylinositol; PS = Phosphatidylserine; PC = Phosphatidylcholine; SM = 
Sphingomyelin.   
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4.4 Protein Analysis by SDS-PAGE 
SDS-PAGE is a great technique to study protein. Many proteins naturally interact 
with each other through disulfide bonds, which can be degraded by using a detergent 
called sodium dodecyl sulfate (SDS). SDS-PAGE was used in this project to analyze 
treated WPI, SBM, and WBM samples to determine if protein aggregation is effected by 
phospholipids and the pH treatment given under reduced and non-reduced conditions. 
Homogenized and the 3
rd 
pass of microfluidized samples at pH 4.6 were compared to 
untreated WPI, SBM, and WBM samples at 6.8 using prestained protein standards as 
molecular markers. The gels were run at 200 V for 40-50 minutes and then stained with 
Coomassie Blue. Trace quantity of the protein bands were quantified using the 
QuantityOne 1-D Analysis software. Trace quantity is determined by the area under the 
intensity profile curve of a band and its units are intensity x mm. 
Protein bands can be visualized in SDS polyacrylamide gels shown in Figure 
4.14. Lanes 2, 5, and 6 represent WPI samples, lanes 3, 6, and 9 represent SBM samples, 
and lanes 4, 7 and 10 represent WBM samples in both SDS gels. The gels can be divided 
into three horizontal sections by molecular weight. MFGM associated proteins like 
xanthine oxidase (XO) and butyrophilin (BTN) are located in the first third, caseins are 
located in the second third, and whey or serum proteins are located on the last third of the 
gel. All WPI and WBM samples contain high intensity bands of whey proteins, while 
SBM samples contain high intensity bands of caseins. SBM and WBM both contain 
bands associated with MFGM proteins, whereas WPI contain very small trace amounts. 
In Figure 4.14(b), large protein and liposomal aggregates remain within the combs of the 
stacking gel because the aggregates are too large to move down the gel.   
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Figure 4.14. SDS-PAGE (15% acrylamide gel) of reconstituted WPI, SBM and WBM 
under (a) reduced and (b) non-reduced conditions. Lane 1. Protein standards; Lane 2. 
WPI untreated at pH 6.8; Lane 3. SBM untreated at pH 6.8; Lane 4. WBM untreated at 
pH 6.8; Lane 5. WPI microfluidized at pH 4.60; Lane 6. SBM microfluidized at pH 4.60; 
Lane 7. WBM microfluidized at pH 4.60; Lane 8. WPI homogenized at pH 4.60; Lane 9. 
SBM homogenized at pH 4.60; Lane 10. WBM homogenized at pH 4.60. Protein Bands: 
XO = xanthine oxidase; BTN = butyrophilin; Pas 6/7 = periodic acid Schiff 6/7; α-CN = 
α-casein; β-CN = β-casein; κ-CN = κ-casein; β-LG = β-lactoglobulin; α-LA = α-
lactalbumin.  
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Trace quantities of milk proteins in each sample are represented in Figure 4.15 
under reduced conditions and Figure 4.16 under non-reduced conditions. Reduced 
samples were treated with 5% β-mercaptoethanol to break down proteins. Both treated 
and untreated WPI samples contain very small traces of MFGM proteins, including BTN 
and Pas 6/7, and equal traces of whey proteins regardless of processing treatments and 
pH (Figure 4.15(a)). Untreated SBM sample at pH 6.8 shows lower quantities of proteins 
compared to microfluidized and homogenized SBM samples at pH 4.6. Figure 4.15(b) 
illustrates that homogenized SBM at pH 4.6 contained higher quantities of caseins and 
whey proteins than the microfluidized SBM. Treated and untreated WBM at both pH 
displays equal trace quantities of whey proteins, but homogenized WBM samples at pH 
4.6 displays slightly greater MFGM associated proteins as well as β-caseins (Figure 
4.15(c)). 
 Under non-reduced conditions and across all WPI samples, the quantity of whey 
proteins remained the same. However, MFGM proteins that were present in the reduced 
samples no longer appear in the non-reduced samples. This is due to the formation of 
large protein aggregates. Large aggregates are too large to flow down 15% acrylamide 
SDS gels and therefore, remain at the top of the stacking gel as demonstrated in Figure 
4.14(b). Additionally, Table 4.9 provides a compositional summary of all samples 
analyzed in this project and it shows that WPI contains residual phospholipids, in which 
may contribute to aggregate formation by phospholipid and protein interactions. In both 
untreated and treated SBM samples, the quantity of MFGM associated proteins, caseins, 
and whey proteins had decreased, which means that some proteins had interactions with 
each other to form large aggregates at both pH (Figure 4.16(b)). Untreated WBM at pH 
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6.8 showed no signs of MFGM related proteins or caseins (Figure 4.16(c)). Treated 
WBM samples at pH 4.6 were consistent with each other in the amount of whey proteins 
and caseins, but inconsistent on the low amount of MFGM associated proteins. These 
results compared to Figure 4.15 indicate that processing and pH may not have an effect 
on protein quantities. Instead, it can be suggested that phospholipids play an interesting 
role in the formation of liposomal aggregates by phospholipid-protein and protein-protein 
interactions. Although further research is needed to fully understand how phospholipids 
and protein interact with each other, this suggestion is feasible because milk proteins are 
adsorbed onto the MFGM during homogenization or microfluidization by some means of 
interaction. However, the mechanism in which they occur would need further 
investigation.   
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Figure 4.15. Trace Quantity (intensity x mm) of SDS-PAGE under reducing conditions 
in (a) WPI, (b) SBM, and (c) WBM samples. 
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Figure 4.16. Trace Quantity (intensity x mm) of SDS-PAGE under non-reducing 
conditions in (a) WPI, (b) SBM, and (c) WBM samples 
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Table 4.9. Compositional summary of WPI, WBM, and SBM products. 
Composition 
Dry Powder 
 
Microfluidization 
 
Homogenization 
No Treatment 
 
pH 4.6 
 
pH 4.6 
WPI WBM SBM 
 
WBMP SBMP 
 
WBMP SBMP 
Total Fat (%)* 0.179 27.400 8.912 
 
8.984 3.226 
 
10.027 3.990 
PL (%)* 0.254 1.666 1.096 
 
0.317 0.276 
 
0.633 0.665 
Protein (%)* 41.578 43.512 47.246 
 
2.000 2.000 
 
2.000 2.000 
Avg. Total Fat 
(g) 
0.002 0.275 0.089 
 
0.095 0.020 
 
0.081 0.023 
Avg. Sample 
Wt. (g) 
1.003 1.003 1.004 
 
1.053 0.615 
 
0.811 0.587 
*All percentages are per approximately 1 gram of solid. 
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5.0 Conclusions 
Incorporating buttermilk powder into food systems has advantages in many ways. 
The addition of buttermilk in baked goods, chocolate, ice cream, cheese, and dressings 
enhances their texture, flavor, and structure due to the abundance of MFGM components, 
especially phospholipids (Costa, Elias-Argote, Jimenez-Flores, & Gigante, 2010). 
MFGM phospholipids have been extensively studied because they possess emulsification 
properties and offer health benefits, such as inhibition of colon cancer and enhancing 
growth and development (Spitsberg, 2005). The focus of this thesis was to study the 
composition and structure of liposomal aggregates made from phospholipids of 
commercial sweet buttermilk and whey buttermilk prepared by microfluidization and 
homogenization. These liposomes can be utilized as delivery systems for bioactive 
components in many industries for various applications.  
Liposomal preparation by microfluidization and homogenization resulted in 
analogous mean particle size differences across all samples and therefore, no significant 
differences were detected between the two shearing techniques. The use of 
homogenization and microfluidization both provoked similar changes in aggregate size, 
from before treatments to after, by creating smaller particle distributions in SBM at pH 
4.6, and the results are in accordance with literature (Thompson & Singh, 2006) 
(Nongonierma, Abrlova, Fenelson, & Kilcawley, 2009). There were significant 
differences in the mean particle size from before processing and after in SBM and WPI at 
pH 4.6 using either shear technique but not in other treatments. The SBM results suggest 
that casein interactions with other milk proteins formed very large aggregates with 
phospholipids since caseins are found in abundance in SBM.  
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In contrast, WBM treated at pH 4.6 and pH 6.8 did not show significant 
differences in their mean particle size at either shear treatments. It can be suggested that 
the enrichment of phospholipids may contribute to the small structures of the aggregates 
in WBM samples. These results also are in agreement with studies by Sodini and 
colleagues (2006). WBM also exhibited similar characteristics as WPI since their particle 
sizes were not significantly different from each other. WBM contained higher 
concentrations of phospholipids compared to WPI, which contained trace amounts left 
behind from processing, and SBM. The abundance of phospholipids within WBM makes 
it an important and beneficial dairy ingredient.  
Differences in phospholipid profiling were seen across all sample types and 
treatment combinations. In addition, homogenization and microfluidization treatments, as 
well as pH conditions, did not greatly affect the phospholipid profiling. This is possibly 
due to heat treatment to 70 ºC at initial conditioning to denature whey proteins. 
Alternatively, proteins may have had interactions with phospholipids during high shear 
treatments causing structural changes. These changes inhibited the full extraction of 
phospholipids and thus, resulted in the differences of phospholipid profiling in treated 
samples. Furthermore, the SDS-PAGE analysis suggests that phospholipids may possibly 
play an important role in aggregate formation via interactions with other milk proteins.  
5.1 Limitations of this Study 
Inevitably, variation occurs in manufacturing and processing practices, 
geographic locations, seasons, and cows. The dairy powders used to conduct research in 
this project were manufactured from different sources and thereby, causing some 
variation. This is important to address because these ingredients were not created using 
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the same batch of milk from the same dairy source. However, the results from this 
research provide quality contributions and suggestive relationships between the 
buttermilk powders. The complexities of the experimental design led to some restrictions 
on the number of samples that could be analyzed and thus, limited the analysis of some 
parameters. In addition, data could not be collected on particle size distribution for WPI 
and SBM at pH 6.8 since these samples were soluble under the treated conditions. No 
experimental design is perfect and complications can naturally arise. Despite the 
complexities, the results from this investigation provided modest contributions to the 
existing research on the MFGM and its phospholipids to be utilized as vehicles for 
bioactive compounds for the delivery of nutrition and beneficial health in future 
applications.  
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6.0 Directions for Future Research 
Interactions between phospholipids and proteins are important to continuously 
study for better understanding their structural changes and functions. Perhaps stronger 
relationships between high shear and the pH condition of aggregates can be detected by 
obtaining or manufacturing dairy ingredients in such a way that reduce variability. 
Modifications to phospholipid extractions can be studied to optimize extraction 
procedures to fully extract phospholipids from samples. Further investigation of particle 
size distribution, phospholipid profiling, and protein content can be performed with 
various concentrations of phospholipids, pH ranges, and thermal conditions. Various 
shear techniques, such as sonication, can be utilized to prepare small liposomal aggregate 
particles in addition to homogenization and microfluidization. Lastly, investigation of the 
encapsulation capacity of bioactive compounds, such as fat soluble vitamins and 
antioxidants, into liposomal aggregates can be utilized as vehicles to deliver nutrition.   
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APPENDICES 
Appendix A: Randomization for Homogenization 
Homogenization Day 1 
Powders pH Randomization Run Order 
SBM 4.6 0.040043249 1 
WBM 6.8 0.315799282 2 
WPI 4.6 0.570297671 3 
WPI 6.8 0.641186231 4 
WBM 4.6 0.679798881 5 
SBM 6.8 0.862066505 6 
    
Homogenization Day 2 
Powders pH Randomization Run Order 
WBM 4.6 0.003241287 1 
WPI 4.6 0.089398186 2 
WPI 6.8 0.476119442 3 
WBM 6.8 0.697712829 4 
SBM 6.8 0.726706819 5 
SBM 4.6 0.739543682 6 
    
Homogenization Day 3 
Powders pH Randomization Run Order 
SBM 6.8 0.074157962 1 
WPI 6.8 0.221086383 2 
SBM 4.6 0.269736291 3 
WPI 4.6 0.810364482 4 
WBM 6.8 0.852048019 5 
WBM 4.6 0.968896785 6 
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Appendix B: Randomization for Microfluidization 
Microfluidization Day 1 
 
Microfluidization Day 4 
Powders pH Randomization Run Order 
 
Powders pH Randomization Run Order 
WBM 4.6 0.116160437 1 
 
WBM 6.8 0.046589733 1 
SBM 6.8 0.158058539 2 
 
SBM 6.8 0.25498164 2 
WPI 6.8 0.454649064 3 
 
WPI 4.6 0.381852791 3 
WPI 4.6 0.705048944 4 
 
SBM 4.6 0.828516249 4 
SBM 4.6 0.708346708 5 
 
WBM 4.6 0.86136854 5 
WBM 6.8 0.834251298 6 
 
WPI 6.8 0.888758399 6 
         
Microfluidization Day 2 
 
Microfluidization Day 5 
Powders pH Randomization Run Order 
 
Powders pH Randomization Run Order 
WPI 4.6 0.370113966 1 
 
WBM 4.6 0.102348806 1 
WPI 6.8 0.446552658 2 
 
WPI 4.6 0.128427148 2 
WBM 6.8 0.540073213 3 
 
WBM 6.8 0.33353294 3 
SBM 4.6 0.559263787 4 
 
SBM 4.6 0.434078138 4 
SBM 6.8 0.731676259 5 
 
SBM 6.8 0.530879443 5 
WBM 4.6 0.761249457 6 
 
WPI 6.8 0.972914692 6 
         
Microfluidization Day 3 
     
Powders pH Randomization Run Order 
     
WBM 4.6 0.206504088 1 
     
WPI 6.8 0.42807719 2 
     
WBM 6.8 0.43794731 3 
     
SBM 4.6 0.469256789 4 
     
SBM 6.8 0.826942774 5 
     
WPI 4.6 0.841389305 6 
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Appendix C: Homogenization Paired Data JMP Output and Model Assumptions 
Response = Difference in diameter (Before – After) 
Factor = Treatment (4 levels:  SBM 4.6, WBM 4.6, WBM 6.8, and WPI 4.6) 
Blocking Factor = Day (3 levels:  1, 2, and 3) 
Estimation Method = Restricted Maximum Likelihood (REML) 
 
Summary of Fit 
RSquare 0.94862 
RSquare Adj 0.929352 
Root Mean Square Error 1.174807 
Mean of Response 4.1425 
Observations (or Sum Wgts) 12 
 
Fixed Effect Tests 
Source Nparm DF DFDen F Ratio Prob > F  
Treatment 3 3 6 57.6674 <.0001*  
 
LSMeans Differences Tukey HSD 
α=0.050 
LSMean[i] By LSMean[j] 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 
SBM4.6 WBM4.6 WBM6.8 WPI4.6 
SBM4.6 0 
0 
0 
0 
11.043 
0.95923 
7.72244 
14.3636 
10.727 
0.95923 
7.40644 
14.0476 
8.11467 
0.95923 
4.79411 
11.4352 
WBM4.6 -11.043 
0.95923 
-14.364 
-7.7224 
0 
0 
0 
0 
-0.316 
0.95923 
-3.6366 
3.00456 
-2.9283 
0.95923 
-6.2489 
0.39222 
WBM6.8 -10.727 
0.95923 
-14.048 
-7.4064 
0.316 
0.95923 
-3.0046 
3.63656 
0 
0 
0 
0 
-2.6123 
0.95923 
-5.9329 
0.70822 
WPI4.6 -8.1147 
0.95923 
-11.435 
-4.7941 
2.92833 
0.95923 
-0.3922 
6.24889 
2.61233 
0.95923 
-0.7082 
5.93289 
0 
0 
0 
0 
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Level       Least Sq Mean 
SBM4.6 A      11.613667 
WPI4.6  B     3.499000 
WBM6.8  B     0.886667 
WBM4.6  B     0.570667 
Levels not connected by same letter are significantly different. 
 
LS Means Plot 
 
Least Squares Means Table 
Level Least Sq Mean  Std Error Lower 98.75% Upper 98.75% 
SBM4.6 11.613667  0.64467026 9.527332 13.700002 
WBM4.6 0.570667  0.64467026 -1.515668 2.657002 
WBM6.8 0.886667  0.64467026 -1.199668 2.973002 
WPI4.6 3.499000  0.64467026 1.412665 5.585335 
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Appendix D: Microfluidization Repeated Measures Data SAS Output 
For overall effects 
Effect 
Num 
DF 
Den 
DF 
F 
Value 
Pr > F 
Trt 3 16 13.48 0.0001 
Pass 3 16 23.82 <.0001 
Trt*Pass 9 16 6.3 0.0008 
 
Tests for Treatment effects (differences between treatments at each pass) 
Effect Trt Pass Num DF Den DF F Value Pr > F 
Trt*Pass SBM4.6 all 3 16 36.76 <.0001 
Trt*Pass WBM4.6 all 3 16 0.9 0.4615 
Trt*Pass WBM6.8 all 3 16 2.11 0.1397 
Trt*Pass WPI4.6 all 3 16 2.95 0.0645 
 
Tests for Pass effects  
Effect Trt Pass Num DF Den DF F Value Pr > F 
Trt*Pass all 0 3 16 22.62 <.0001 
Trt*Pass all 1 3 16 2.34 0.1116 
Trt*Pass all 2 3 16 4.04 0.0258 
Trt*Pass all 3 3 16 3.49 0.0404 
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Estimated Difference by Treatments 
SBM 4.6 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Val-
ue 
Pr>|t| 
Adjust-
ment 
Adj. P 
Trt*Pass 
SBM
4.6 
0 
SBM
4.6 
1 6.9622 0.7442 16 9.36 <.0001 
Tukey-
Kramer 
<.0001 
Trt*Pass 
SBM
4.6 
0 
SBM
4.6 
2 7.837 0.8536 16 9.18 <.0001 
Tukey-
Kramer 
<.0001 
Trt*Pass 
SBM
4.6 
0 
SBM
4.6 
3 8.4344 0.8827 16 9.56 <.0001 
Tukey-
Kramer 
<.0001 
Trt*Pass 
SBM
4.6 
1 
SBM
4.6 
2 0.8748 0.5382 16 1.63 0.124 
Tukey-
Kramer 
0.94 
Trt*Pass 
SBM
4.6 
1 
SBM
4.6 
3 1.4722 0.6463 16 2.28 0.037 
Tukey-
Kramer 
0.642 
Trt*Pass 
SBM
4.6 
2 
SBM
4.6 
3 0.5974 0.2637 16 2.27 0.038 
Tukey-
Kramer 
0.649 
 
WBM 4.6 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Val-
ue 
Pr>|t| 
Adjust-
ment 
Adj P 
Trt*Pass 
WBM
4.6 
0 
WBM
4.6 
1 0.9246 0.7442 16 1.24 0.232 
Tukey-
Kramer 
0.993 
Trt*Pass 
WBM
4.6 
0 
WBM
4.6 
2 1.4014 0.8536 16 1.64 0.12 
Tukey-
Kramer 
0.936 
Trt*Pass 
WBM
4.6 
0 
WBM
4.6 
3 1.411 0.8827 16 1.6 0.13 
Tukey-
Kramer 
0.947 
Trt*Pass 
WBM
4.6 
1 
WBM
4.6 
2 0.4768 0.5382 16 0.89 0.389 
Tukey-
Kramer 
1 
Trt*Pass 
WBM
4.6 
1 
WBM
4.6 
3 0.4864 0.6463 16 0.75 0.463 
Tukey-
Kramer 
1 
Trt*Pass 
WBM
4.6 
2 
WBM
4.6 
3 0.0096 0.2637 16 0.04 0.971 
Tukey-
Kramer 
1 
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WBM 6.8 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Val-
ue 
Pr>|t| 
Adjust-
ment 
Adj P 
Trt*Pass 
WBM
6.8 
0 
WBM
6.8 
1 0.9448 0.7442 16 1.27 0.222 
Tukey-
Kramer 
0.992 
Trt*Pass 
WBM
6.8 
0 
WBM
6.8 
2 1.0542 0.8536 16 1.24 0.235 
Tukey-
Kramer 
0.994 
Trt*Pass 
WBM
6.8 
0 
WBM
6.8 
3 1.5488 0.8827 16 1.75 0.099 
Tukey-
Kramer 
0.901 
Trt*Pass 
WBM
6.8 
1 
WBM
6.8 
2 0.1094 0.5382 16 0.2 0.842 
Tukey-
Kramer 
1 
Trt*Pass 
WBM
6.8 
1 
WBM
6.8 
3 0.604 0.6463 16 0.93 0.364 
Tukey-
Kramer 
1 
Trt*Pass 
WBM
6.8 
2 
WBM
6.8 
3 0.4946 0.2637 16 1.88 0.079 
Tukey-
Kramer 
0.854 
 
WPI 4.6 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Val-
ue 
Pr>|t| 
Adjust-
ment 
Adj P 
Trt*Pass 
WPI
4.6 
0 
WPI
4.6 
1 1.9566 0.7442 16 2.63 0.018 
Tukey-
Kramer 
0.441 
Trt*Pass 
WPI
4.6 
0 
WPI
4.6 
2 2.41 0.8536 16 2.82 0.012 
Tukey-
Kramer 
0.343 
Trt*Pass 
WPI
4.6 
0 
WPI
4.6 
3 2.4938 0.8827 16 2.83 0.012 
Tukey-
Kramer 
0.342 
Trt*Pass 
WPI
4.6 
1 
WPI
4.6 
2 0.4534 0.5382 16 0.84 0.412 
Tukey-
Kramer 
1 
Trt*Pass 
WPI
4.6 
1 
WPI
4.6 
3 0.5372 0.6463 16 0.83 0.418 
Tukey-
Kramer 
1 
Trt*Pass 
WPI
4.6 
2 
WPI
4.6 
3 0.0838 0.2637 16 0.32 0.755 
Tukey-
Kramer 
1 
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Estimated Differences by Pass 
Pass 0 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Value 
Pr>|t| 
Adjust-
ment 
Adj P 
Trt*Pass SBM4.6 0 WBM4.6 0 8.2716 1.1604 16 7.13 <.0001 
Tukey-
Kramer 
0.0002 
Trt*Pass SBM4.6 0 WBM6.8 0 8.2266 1.1604 16 7.09 <.0001 
Tukey-
Kramer 
0.0002 
Trt*Pass SBM4.6 0 WPI4.6 0 6.1568 1.1604 16 5.31 <.0001 
Tukey-
Kramer 
0.0045 
Trt*Pass WBM4.6 0 WBM6.8 0 -0.045 1.1604 16 -0.04 0.97 
Tukey-
Kramer 
1 
Trt*Pass WBM4.6 0 WPI4.6 0 -2.115 1.1604 16 -1.82 0.087 
Tukey-
Kramer 
0.876 
Trt*Pass WBM6.8 0 WPI4.6 0 -2.07 1.1604 16 -1.78 0.093 
Tukey-
Kramer 
0.8908 
 
Pass 1 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Value 
Pr>|t| 
Adjust-
ment 
Adj P 
Trt*Pass SBM4.6 1 WBM4.6 1 2.234 0.9794 16 2.28 0.037 
Tukey-
Kramer 
0.6403 
Trt*Pass SBM4.6 1 WBM6.8 1 2.2092 0.9794 16 2.26 0.039 
Tukey-
Kramer 
0.6551 
Trt*Pass SBM4.6 1 WPI4.6 1 1.1512 0.9794 16 1.18 0.257 
Tukey-
Kramer 
0.9959 
Trt*Pass WBM4.6 1 WBM6.8 1 -0.025 0.9794 16 -0.03 0.98 
Tukey-
Kramer 
1 
Trt*Pass WBM4.6 1 WPI4.6 1 -1.083 0.9794 16 -1.11 0.285 
Tukey-
Kramer 
0.9978 
Trt*Pass WBM6.8 1 WPI4.6 1 -1.058 0.9794 16 -1.08 0.296 
Tukey-
Kramer 
0.9983 
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Pass 2 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Value 
Pr>|t| 
Adjust-
ment 
Adj P 
Trt*Pass SBM4.6 2 WBM4.6 2 1.836 0.5703 16 3.22 0.005 
Tukey-
Kramer 
0.191 
Trt*Pass SBM4.6 2 WBM6.8 2 1.4438 0.5703 16 2.53 0.022 
Tukey-
Kramer 
0.4943 
Trt*Pass SBM4.6 2 WPI4.6 2 0.7298 0.5703 16 1.28 0.219 
Tukey-
Kramer 
0.991 
Trt*Pass WBM4.6 2 WBM6.8 2 -0.392 0.5703 16 -0.69 0.502 
Tukey-
Kramer 
1 
Trt*Pass WBM4.6 2 WPI4.6 2 -1.106 0.5703 16 -1.94 0.07 
Tukey-
Kramer 
0.8252 
Trt*Pass WBM6.8 2 WPI4.6 2 -0.714 0.5703 16 -1.25 0.229 
Tukey-
Kramer 
0.9927 
 
Pass 3 
Effect Trt Pass Trt Pass Mean 
Std 
Error 
DF 
t  
Value 
Pr>|t| 
Adjust-
ment 
Adj P 
Trt*Pass SBM4.6 3 WBM4.6 3 1.2482 0.5236 16 2.38 0.03 
Tukey-
Kramer 
0.5797 
Trt*Pass SBM4.6 3 WBM6.8 3 1.341 0.5236 16 2.56 0.021 
Tukey-
Kramer 
0.4778 
Trt*Pass SBM4.6 3 WPI4.6 3 0.2162 0.5236 16 0.41 0.685 
Tukey-
Kramer 
1 
Trt*Pass WBM4.6 3 WBM6.8 3 0.0928 0.5236 16 0.18 0.862 
Tukey-
Kramer 
1 
Trt*Pass WBM4.6 3 WPI4.6 3 -1.032 0.5236 16 -1.97 0.066 
Tukey-
Kramer 
0.8102 
Trt*Pass WBM6.8 3 WPI4.6 3 -1.125 0.5236 16 -2.15 0.047 
Tukey-
Kramer 
0.7166 
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Appendix E: Homogenization and Microfluidization Combined Paired Data JMP 
Output and Model Assumptions 
Response = Difference in diameter (Before – After) 
Factor = Treatment (8 levels:  SBM 4.6 Homog, WBM 4.6 Homog, WBM 6.8 Homog, 
WPI 4.6 Homog, SBM 4.6 MF, WBM 4.6 MF, WBM 6.8 MF, and WPI 4.6 MF) 
Blocking Factor = Day (3 levels:  1, 2, and 3) 
Estimation Method = Restricted Maximum Likelihood (REML) 
 
Summary of Fit 
RSquare 0.885174 
RSquare Adj 0.851683 
Root Mean Square Error 1.602802 
Mean of Response 3.723438 
Observations (or Sum Wgts) 32 
 
 
Fixed Effect Tests 
Source Nparm DF DFDen F Ratio Prob > F  
Treatment 7 7 17.71 21.9457 <.0001*  
 
  
99 
 
LSMeans Differences Tukey HSD 
α=0.050 
LSMean[i] By LSMean[j] 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 
SBM4.6Homog SBM4.6MF WBM4.6Homog WBM4.6MF WBM6.8Homog WBM6.8MF WPI4.6Homog WPI4.6MF 
SBM4.6Homog 0 
0 
0 
0 
3.17927 
1.2676 
-1.0432 
7.40175 
11.043 
1.30868 
6.57868 
15.5073 
10.2027 
1.2676 
5.98018 
14.4252 
10.727 
1.30868 
6.26268 
15.1913 
10.0649 
1.2676 
5.84238 
14.2874 
8.11467 
1.30868 
3.65034 
12.579 
9.11987 
1.2676 
4.89738 
13.3424 
SBM4.6MF -3.1793 
1.2676 
-7.4018 
1.04322 
0 
0 
0 
0 
7.86373 
1.2676 
3.64125 
12.0862 
7.0234 
1.0137 
3.56535 
10.4814 
7.54773 
1.2676 
3.32525 
11.7702 
6.8856 
1.0137 
3.42755 
10.3436 
4.9354 
1.2676 
0.71292 
9.15788 
5.9406 
1.0137 
2.48255 
9.39865 
WBM4.6Homog -11.043 
1.30868 
-15.507 
-6.5787 
-7.8637 
1.2676 
-12.086 
-3.6412 
0 
0 
0 
0 
-0.8403 
1.2676 
-5.0628 
3.38215 
-0.316 
1.30868 
-4.7803 
4.14832 
-0.9781 
1.2676 
-5.2006 
3.24435 
-2.9283 
1.30868 
-7.3927 
1.53599 
-1.9231 
1.2676 
-6.1456 
2.29935 
WBM4.6MF -10.203 
1.2676 
-14.425 
-5.9802 
-7.0234 
1.0137 
-10.481 
-3.5654 
0.84033 
1.2676 
-3.3822 
5.06282 
0 
0 
0 
0 
0.52433 
1.2676 
-3.6982 
4.74682 
-0.1378 
1.0137 
-3.5958 
3.32025 
-2.088 
1.2676 
-6.3105 
2.13448 
-1.0828 
1.0137 
-4.5408 
2.37525 
WBM6.8Homog -10.727 
1.30868 
-15.191 
-6.2627 
-7.5477 
1.2676 
-11.77 
-3.3252 
0.316 
1.30868 
-4.1483 
4.78032 
-0.5243 
1.2676 
-4.7468 
3.69815 
0 
0 
0 
0 
-0.6621 
1.2676 
-4.8846 
3.56035 
-2.6123 
1.30868 
-7.0767 
1.85199 
-1.6071 
1.2676 
-5.8296 
2.61535 
WBM6.8MF -10.065 
1.2676 
-14.287 
-5.8424 
-6.8856 
1.0137 
-10.344 
-3.4276 
0.97813 
1.2676 
-3.2444 
5.20062 
0.1378 
1.0137 
-3.3202 
3.59585 
0.66213 
1.2676 
-3.5604 
4.88462 
0 
0 
0 
0 
-1.9502 
1.2676 
-6.1727 
2.27228 
-0.945 
1.0137 
-4.403 
2.51305 
WPI4.6Homog -8.1147 
1.30868 
-12.579 
-3.6503 
-4.9354 
1.2676 
-9.1579 
-0.7129 
2.92833 
1.30868 
-1.536 
7.39266 
2.088 
1.2676 
-2.1345 
6.31048 
2.61233 
1.30868 
-1.852 
7.07666 
1.9502 
1.2676 
-2.2723 
6.17268 
0 
0 
0 
0 
1.0052 
1.2676 
-3.2173 
5.22768 
WPI4.6MF -9.1199 
1.2676 
-13.342 
-4.8974 
-5.9406 
1.0137 
-9.3986 
-2.4826 
1.92313 
1.2676 
-2.2994 
6.14562 
1.0828 
1.0137 
-2.3752 
4.54085 
1.60713 
1.2676 
-2.6154 
5.82962 
0.945 
1.0137 
-2.513 
4.40305 
-1.0052 
1.2676 
-5.2277 
3.21728 
0 
0 
0 
0 
 
 
Level       Least Sq 
Mean 
SBM4.6Homog A      11.613667 
SBM4.6MF A      8.434400 
WPI4.6Homog  B     3.499000 
WPI4.6MF  B     2.493800 
WBM6.8MF  B     1.548800 
WBM4.6MF  B     1.411000 
WBM6.8Homog  B     0.886667 
WBM4.6Homog  B     0.570667 
Levels not connected by same letter are significantly different. 
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LS Means Plot 
 
 
Least Squares Means Table 
Level Least Sq Mean  Std Error Lower 99.37% Upper 99.37% 
SBM4.6Homog 11.613667  1.0021242 8.595002 14.632331 
SBM4.6MF 8.434400  0.7762421 6.096153 10.772647 
WBM4.6Homog 0.570667  1.0021242 -2.447998 3.589331 
WBM4.6MF 1.411000  0.7762421 -0.927247 3.749247 
WBM6.8Homog 0.886667  1.0021242 -2.131998 3.905331 
WBM6.8MF 1.548800  0.7762421 -0.789447 3.887047 
WPI4.6Homog 3.499000  1.0021242 0.480336 6.517664 
WPI4.6MF 2.493800  0.7762421 0.155553 4.832047 
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Appendix F: HPLC Calibration Curves 
Day 1 
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Day 2 
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Day 3 
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